risperidone has been researched along with Autistic Disorder in 164 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Autistic Disorder: A disorder beginning in childhood. It is marked by the presence of markedly abnormal or impaired development in social interaction and communication and a markedly restricted repertoire of activity and interest. Manifestations of the disorder vary greatly depending on the developmental level and chronological age of the individual. (DSM-V)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Forty-three children with autism (6-12 years old) randomly were divided into three groups: risperidone (n = 15), risperidone + VR (n = 15), and control (n = 13)." | 9.41 | Comparing the Effect of Risperidone, Virtual Reality and Risperidone on Social Skills, and Behavioral Problems in Children with Autism: A Follow-up Randomized Clinical Trial. ( Arabi, SM; Khosrorad, R; Soltani Kouhbanani, S; Zarenezhad, S, 2021) |
| "In this randomized, double-blind, placebo-controlled, parallel-group 10-week clinical trial, 70 drug-free children aged 4 to 12 years old with diagnosis of autistic disorder based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, who had an Aberrant Behavior Checklist-Community (ABC-C) scale irritability subscale score of ≥12, were equally randomized to receive either simvastatin (20-40 mg/day) or placebo as an adjunct to risperidone (1-2 mg/day) whereas administration of both drugs was started simultaneously from baseline." | 9.27 | Simvastatin as an Adjunctive Therapy to Risperidone in Treatment of Autism: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. ( Akhondzadeh, S; Karkhaneh-Yousefi, MA; Khezri, R; Moazen-Zadeh, E; Mohammadi, MR; Shirzad, F, 2018) |
| "This study aimed at investigating the efficacy and tolerability of l-carnosine as an add-on to risperidone in the management of children with autism." | 9.27 | l-Carnosine As an Adjunctive Therapy to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. ( Afarideh, M; Akhondzadeh, S; Ghajar, A; Hajizadeh-Zaker, R; Mesgarpour, B; Mohammadi, MR, 2018) |
| "Risperidone is a common psychopharmacological treatment for irritability in autism spectrum disorder (ASD)." | 9.22 | Initial severity and efficacy of risperidone in autism: Results from the RUPP trial. ( Furukawa, TA; Goldberg, Y; Kodesh, A; Kolevzon, A; Leucht, S; Levine, SZ; Reichenberg, A, 2016) |
| "This is an investigation of minocycline efficacy and safety as an adjuvant to risperidone in management of children with autism." | 9.22 | Minocycline as Adjunctive Treatment to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind Placebo-Controlled Trial. ( Akhondzadeh, S; Alikhani, R; Ghaleiha, A; Hamedi, M; Kazemi, MR; Keshavarzi, Z; Mohammadi, MR; Mohammadinejad, P; Shahriari, M; Zeinoddini, A, 2016) |
| "This clinical trial supports that low dose buspirone plus risperidone is more effective than risperidone plus placebo for treating irritability in individuals with autism." | 9.20 | A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism. ( Ayoobzadehshirazi, A; Ghanizadeh, A, 2015) |
| "To assess the safety and efficacy of pioglitazone added to risperidone in the treatment of irritability in autistic disorder (AD), we conducted this study." | 9.20 | A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: Effects on aberrant behavior in children with autism. ( Akhondzadeh, S; Farokhnia, M; Ghaleiha, A; Mohammadi, MR; Nikoo, M; Rasa, SM, 2015) |
| "Risperidone has demonstrated efficacy for acute (8 week) and intermediate length (6 month) management of severe irritability and aggression in children and adolescents with autism." | 9.20 | Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial. ( Aman, M; Arnold, LE; Ghuman, J; Grados, M; Hellings, J; Hollway, JA; McCracken, J; McDougle, CJ; Nagaraja, HN; Posey, DJ; Rettiganti, M; Scahill, L; Shah, B; Swiezy, NB; Tierney, E; Vitiello, B, 2015) |
| "Aripiprazole and risperidone are the only FDA approved medications for treating irritability in autistic disorder, however there are no head-to-head data comparing these agents." | 9.19 | A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. ( Berk, M; Ghanizadeh, A; Sahraeizadeh, A, 2014) |
| "Two cytokines, eotaxin and MCP-1, which have previously been identified as abnormally elevated in children with autism, decreased during treatment with risperidone." | 9.19 | Change in plasma cytokine levels during risperidone treatment in children with autism. ( Ashwood, P; Bent, S; Careaga, M; Choi, JE; Hendren, RL; Widjaja, F, 2014) |
| "Riluzole add-on therapy shows several therapeutic outcomes, particularly for improving irritability, in children with autism." | 9.17 | Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial. ( Akhondzadeh, S; Ashrafi, M; Farokhnia, M; Ghaleiha, A; Hassanzadeh, E; Modabbernia, A; Mohammadi, E; Mohammadi, MR; Yekehtaz, H, 2013) |
| "The purpose of this study was to evaluate the long-term safety and efficacy of risperidone in treating irritability and related behaviors in children and adolescents with autistic disorders." | 9.17 | An open-label extension study of the safety and efficacy of risperidone in children and adolescents with autistic disorder. ( Hough, D; Karcher, K; Kent, JM; Pandina, G; Singh, J, 2013) |
| "In a 10-week randomized double-blind placebo-controlled study, 40 outpatient children with a Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision clinical diagnosis of autism were randomly allocated to celecoxib plus risperidone or placebo plus risperidone." | 9.17 | Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. ( Akhondzadeh, S; Asadabadi, M; Ashrafi, M; Forghani, S; Ghanizadeh, A; Hassanzadeh, E; Modabbernia, A; Mohammadi, MR, 2013) |
| "Efficacy and safety of 2 risperidone doses were evaluated in children and adolescents with autism." | 9.17 | Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study. ( Aman, M; Hough, D; Karcher, K; Kent, JM; Kushner, S; Ness, S; Ning, X; Singh, J, 2013) |
| "Risperidone has been shown to improve serious behavioral problems in children with autism." | 9.15 | Risperidone-related improvement of irritability in children with autism is not associated with changes in serum of epidermal growth factor and interleukin-13. ( Aman, MG; Arnold, LE; Bothwell, AL; Chae, W; Hoekstra, PJ; Katsovich, L; Kawikova, I; Leckman, JF; McCracken, JT; McDougle, CJ; Scahill, L; Tierney, E; Tobiasova, Z; van der Lingen, KH; Vitiello, B; Volkmar, F; Zhang, Y, 2011) |
| "The results suggest that combination of atypical antipsychotic medications and pentoxifylline might have synergistic effects in treatment of behavioral problems of children with autism." | 9.14 | Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. ( Akhondzadeh, S; Fallah, J; Forghani, S; Ghanizadeh, A; Imani, R; Mohammadi, M; Mohammadi, MR; Mohebbi-Rasa, S; Raznahan, M; Rezazadeh, SA; Salehi, B, 2010) |
| " The present study assessed the effects of topiramate plus risperidone in the treatment of autistic disorder." | 9.14 | Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. ( Akhondzadeh, S; Ghanizadeh, A; Mohammadi, MR; Rezaei, V; Rezazadeh, SA; Sahraian, A; Tabrizi, M, 2010) |
| "The objective of this research was to explore the effects of risperidone on cognitive processes in children with autism and irritable behavior." | 9.13 | Cognitive effects of risperidone in children with autism and irritable behavior. ( Aman, MG; Arnold, LE; Cronin, P; Gavaletz, A; Ghuman, JK; Hollway, JA; Koenig, K; McCracken, JT; McDougle, CJ; Posey, DJ; Ritz, L; Scahill, L; Swiezy, N; Tierney, E; Vitiello, B; Wheeler, C, 2008) |
| " Therefore, it was of interest to assess the efficacy of piracetam, a positive modulator of AMPA-sensitive glutamate receptors in autistic disorder." | 9.13 | A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder. ( Akhondzadeh, S; Ghelichnia, HA; Mohammadi, M; Mohammadi, MR; Nouroozinejad, GH; Shabstari, OL; Tajdar, H, 2008) |
| "The aim of the study was to investigate safety, efficacy and tolerability of risperidone in comparison with haloperidol in the long-term treatment of autistic disorder." | 9.13 | Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. An open label maintenance study. ( Baykara, A; Baykara, B; Dirik, E; Emiroglu, FN; Gencer, O; Miral, S, 2008) |
| "We report on an open-label, naturalistic study using risperidone to treat disruptive behaviors and self-injury in children with Down syndrome, severe intellectual disability, and comorbid autism spectrum disorders (DS+ASDs)." | 9.13 | Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: a naturalistic study. ( Capone, GT; Goyal, P; Grados, M; Kammann, H; Smith, B, 2008) |
| " The aim of this study was to investigate the phenomenology of SIB in a group of children with autistic disorder, and to test whether treatment with risperidone might reduce it." | 9.12 | Self injurious behavior in autism: clinical aspects and treatment with risperidone. ( Canitano, R, 2006) |
| "To evaluate the impact of risperidone on adaptive behavior in children with autistic disorder who have serious behavior problems and to examine different methods of scoring the Vineland Adaptive Behavior Scales to measure change." | 9.12 | Risperidone and adaptive behavior in children with autism. ( Aman, MG; Arnold, LE; Cicchetti, D; Cronin, P; Ghuman, J; Hollway, J; McCracken, JT; McDougle, CJ; Posey, DJ; Ritz, L; Scahill, L; Sparrow, S; Swiezy, NB; Tierney, E; Vitiello, B; Wheeler, C; Williams, SK, 2006) |
| "The effects of short- and long-term risperidone treatment on serum prolactin were assessed in children and adolescents with autism." | 9.12 | Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. ( Aman, MG; Anderson, GM; Arnold, LE; Katsovich, L; Martin, A; McCracken, JT; McDougle, CJ; Posey, DJ; Scahill, L; Shah, B; Tierney, E; Vitiello, B, 2007) |
| "Some open-label studies suggest that risperidone can be useful in the treatment of certain target symptoms in children with autism." | 9.12 | Risperidone in children with autism: randomized, placebo-controlled, double-blind study. ( Malhi, P; Nagaraj, R; Singhi, P, 2006) |
| "Subgroup analysis of children (5-12 years) with autism enrolled in an 8-week, double-blind, placebo-controlled trial of risperidone for pervasive developmental disorders." | 9.12 | Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. ( Bossie, CA; Dunbar, F; Pandina, GJ; Youssef, E; Zhu, Y, 2007) |
| "Parents of 101 children with autism who had participated in a multi-site 8-week double-blind clinical trial of risperidone were given a questionnaire at the end to elicit their perceptions of the appropriateness and acceptability of clinical trial procedures." | 9.12 | Parent satisfaction in a multi-site acute trial of risperidone in children with autism: a social validity study. ( Aman, M; Arnold, LE; Martin, A; McCracken, J; McDougle, C; Pappas, K; Posey, D; Scahill, L; Shah, B; Stout, D; Tierney, E; Vitiello, B; Wheeler, C, 2007) |
| "Risperidone may be effective in improving tantrums, aggression, or self-injurious behaviour in children with autism, but often leads to weight gain." | 9.12 | Dietary status and impact of risperidone on nutritional balance in children with autism: a pilot study. ( Aman, MG; Bozzolo, D; Eugene Arnold, L; Lindsay, RL; McCracken, JT; McDougle, CJ; Pachler, M; Posey, DJ; Scahill, L; Tierney, E; Vitiello, B, 2006) |
| "The aim of the present study was to evaluate the effectiveness and tolerability of risperidone in children with autistic disorder and to examine the correlation between plasma levels of risperidone and its active metabolite 9-hydroxyrisperidone (9-OH-risperidone) and the clinical response." | 9.11 | Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. ( Calamoneri, F; D'Arrigo, C; Gagliano, A; Germanò, E; Impallomeni, C; Pustorino, G; Spina, E, 2004) |
| "Weight change was measured for 63 children and adolescents with autism treated with risperidone for 6 months." | 9.11 | Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. ( Aman, M; Anderson, GM; Arnold, LE; Chuang, S; Martin, A; McCracken, J; McDougle, CJ; Scahill, L; Tierney, E; Vitiello, B, 2004) |
| "Risperidone has been found efficacious for decreasing severe tantrums, aggression, and self-injurious behavior in children and adolescents with autistic disorder (autism)." | 9.11 | Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. ( Aman, MG; Arnold, LE; Chuang, SZ; Davies, M; Ghuman, JK; Gonzalez, NM; Hollway, J; Koenig, K; Martin, A; McCracken, JT; McDougle, CJ; McGough, JJ; Posey, DJ; Ritz, L; Scahill, L; Shah, B; Swiezy, NB; Tierney, E; Vitiello, B, 2005) |
| "Risperidone is effective for short-term treatment of aggression, temper outbursts, and self-injurious behavior in children with autism." | 9.11 | Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. ( , 2005) |
| "The short-term benefit of risperidone in ameliorating severe disruptive behavior in pediatric patients with autism spectrum disorders is well established; however, only one placebo-controlled, long-term study of efficacy is available." | 9.11 | Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. ( Buitelaar, JK; Hoekstra, PJ; Ketelaars, CE; Lahuis, BE; Minderaa, RB; Scahill, L; Steenhuis, MP; Troost, PW; van Engeland, H, 2005) |
| "We conducted a multisite, randomized, double-blind trial of risperidone as compared with placebo for the treatment of autistic disorder accompanied by severe tantrums, aggression, or self-injurious behavior in children 5 to 17 years old." | 9.10 | Risperidone in children with autism and serious behavioral problems. ( Aman, MG; Arnold, LE; Carroll, D; Cronin, P; Davies, M; Ghuman, J; Gonzalez, NM; Grados, M; Hollway, J; Hong, D; Koenig, K; Kohn, A; Lancor, A; Lindsay, R; Martin, A; McCracken, JT; McDougle, CJ; McGough, J; McMahon, D; Nash, P; Posey, D; Ritz, L; Robinson, J; Scahill, L; Shah, B; Swiezy, N; Tierney, E; Vitiello, B; Volkmar, F, 2002) |
| "In the Research Units on Pediatric Psychopharmacology (RUPP) Autism Network 8-week double-blind trial of risperidone versus placebo, the chief concerns of parents were collected at 0, 4, and 8 weeks (endpoint), in addition to standardized primary measures." | 9.10 | Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. ( Aman, MG; Arnold, LE; Chuang, S; Cronin, P; Davies, M; Gonzalez, NM; Hollway, J; Koenig, K; Kohn, AE; McDougle, C; McMahon, DJ; Scahill, L; Shah, B; Tierney, E; Vitiello, B, 2003) |
| "Atypical neuroleptics, including risperidone, are used to treat children with autism, despite limited efficacy and safety data." | 9.10 | Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. ( Choudhury, MS; Delaney, MA; Gifford, C; Maislin, G; Malone, RP, 2002) |
| "As part of an ongoing, prospective, ABA design, double-blind crossover study of risperidone versus placebo for the treatment of aggressive, destructive and self-injurious behavior in persons aged 6-65 years with mental retardation (MR) and autism, we measured the weight of 19 subjects at each study visit." | 9.09 | Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. ( Crandall, K; Hellings, JA; Schroeder, SR; Wallace, D; Zarcone, JR, 2001) |
| "To describe the methodological challenges and decisions made in developing a multisite, controlled study of risperidone in children and adolescents with autism." | 9.09 | Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism. ( Aman, M; Arnold, LE; Cronin, P; Davies, M; Ghuman, J; Gonzalez, N; Koenig, K; Lindsay, R; Martin, A; McCracken, J; McDougle, CJ; McGough, J; Posey, DJ; Ritz, L; Scahill, L; Swiezy, N; Tierney, E; Vitiello, B; Volkmar, F, 2001) |
| "Risperidone is more effective than placebo in the short-term treatment of symptoms of autism in adults." | 9.08 | A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. ( Carlson, DC; Cohen, DJ; Holmes, JP; McDougle, CJ; Pelton, GH; Price, LH, 1998) |
| "The pharmacokinetics, pharmacodynamics, safety and efficacy data on aripiprazole for the treatment of irritability associated with autism are discussed." | 8.87 | Aripiprazole for the treatment of irritability associated with autism. ( Aman, MG; Farmer, CA, 2011) |
| "To determine the efficacy and safety of risperidone for people with autism spectrum disorder." | 8.84 | Risperidone for autism spectrum disorder. ( Aref-Adib, M; Coren, E; Jesner, OS, 2007) |
| "To review the clinical trials investigating the efficacy and safety of risperidone in the treatment of children with autism spectrum disorder (ASD)." | 8.83 | Role of risperidone in children with autism spectrum disorder. ( Chavez, B; Chavez-Brown, M; Rey, JA, 2006) |
| "This article has reviewed the background and rationale for the choice of risperidone as the first drug to be studied by the RUPP Autism Network." | 8.80 | Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone. ( Aman, MG; Arnold, LE; Cronin, P; Freeman, BJ; Martin, A; McCracken, JT; McDougle, CJ; McGough, JJ; Posey, DJ; Riddle, MA; Ritz, L; Scahill, L; Swiezy, NB; Tierney, E; Vitiello, B; Volkmar, FR; Votolato, NA; Walson, P, 2000) |
| "Risperidone is the first antipsychotic to be approved by Food and Drug Administration (FDA) for treating autism spectrum disorder (ASD)." | 8.31 | The comparative effectiveness of metformin and risperidone in a rat model of valproic acid-induced autism, Potential role for enhanced autophagy. ( Ashour, RH; Atia, AA; Rahman, KM; Ramadan, NM; Zaki, MM, 2023) |
| " Here, authors report on a challenging case of low-functioning ASD child with comorbid ARFID and misophonia that responded favorably to a low-dose risperidone." | 8.12 | Low-Dose Risperidone for an Autistic Child with Comorbid ARFID and Misophonia. ( Abuzeid, MY; Al-Humoud, AM; Elsori, D; Naguy, A; Pridmore, S; Singh, A, 2022) |
| "We report several cases in which patients with autistic disorder with mental retardation who received risperidone experienced urinary incontinence." | 7.80 | Risperidone-associated urinary incontinence in patients with autistic disorder with mental retardation. ( Imasaka, Y; Iwata, K; Kumazaki, H; Mimura, M; Tomoda, A; Watanabe, K, 2014) |
| "To study the effect of risperidone treatment on behavioral disorders in children with autism." | 7.77 | [Treatment of behavioral disorders by risperidone in children with autism]. ( Huang, F; Liang, QQ; Qin, XT; Wei, BY, 2011) |
| "2 in favor of risperidone on the main outcome measure in an 8-week double-blind, placebo-controlled trial for irritability in autistic disorder." | 7.76 | Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability. ( Aman, MG; Arnold, LE; Chuang, S; Davies, M; DiSilvestro, R; Farmer, C; Kraemer, HC; McCracken, J; McDougle, CJ; Posey, DJ; Scahill, L; Swiezy, NB; Vitiello, B; Witwer, A, 2010) |
| "Two children aged 11 and 10 years, diagnosed with autism and mental retardation, have developed new-onset diurnal and nocturnal enuresis respectively on their first and second weeks of risperidone monotherapy (1." | 7.74 | Risperidone-induced enuresis in two children with autistic disorder. ( Hergüner, S; Mukaddes, NM, 2007) |
| "This report describes the use of risperidone in the treatment of two very young children with autistic disorder, a 29-month-old boy and a 23-month-old boy, respectively." | 7.70 | Risperidone in the treatment of two very young children with autism. ( McDougle, CJ; Posey, DJ; Walsh, KH; Wilson, GA, 1999) |
| "Children with autism were randomly allocated to risperidone plus memantine or placebo plus risperidone for a 10-wk, double-blind, placebo-controlled study." | 6.78 | Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. ( Akhondzadeh, S; Asadabadi, M; Ghaleiha, A; Hajiaghaee, R; Hassanzadeh, E; Mohammadi, MR; Shahei, M; Tabrizi, M, 2013) |
| "Treatment-emergent adverse events (AEs) were monitored during an 8-week, double-blind, placebo-controlled trial of risperidone (0." | 6.71 | Acute and long-term safety and tolerability of risperidone in children with autism. ( Aman, MG; Arnold, LE; Chuang, S; Davies, M; Ghuman, JK; Gonzalez, NM; Koenig, K; Lindsay, RL; Martin, A; McCracken, JT; McDougle, CJ; McGough, J; Nash, PL; Posey, DJ; Ritz, L; Scahill, L; Shah, B; Swiezy, NB; Tierney, E; Vitiello, B, 2005) |
| "Risperidone has been described as having salutary effects as an adjunctive pharmacotherapy in adult and pediatric patients with AD." | 6.68 | An open clinical trial of risperidone monotherapy in young children with autistic disorder. ( Findling, RL; Maxwell, K; Wiznitzer, M, 1997) |
| "Oral risperidone treatment was better than placebo treatment in reducing irritability and other behavioral symptoms associated with autistic disorder in children and adolescents in two well designed short-term trials, with these benefits maintained in those receiving risperidone for up to 6 months." | 6.44 | Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents. ( Dhillon, S; Scott, LJ, 2007) |
| "Autistic disorder (autism) is a neuropsychiatric syndrome characterized by marked deficits in reciprocal social relatedness, communication impairment and a narrow range of interests and/or repetitive behaviors." | 6.41 | Risperidone: a potential treatment for autism. ( McDougle, CJ; Posey, DJ, 2002) |
| "Forty-three children with autism (6-12 years old) randomly were divided into three groups: risperidone (n = 15), risperidone + VR (n = 15), and control (n = 13)." | 5.41 | Comparing the Effect of Risperidone, Virtual Reality and Risperidone on Social Skills, and Behavioral Problems in Children with Autism: A Follow-up Randomized Clinical Trial. ( Arabi, SM; Khosrorad, R; Soltani Kouhbanani, S; Zarenezhad, S, 2021) |
| "Many of children with autism have hyperacusia, an increased sensation to sound." | 5.35 | Does risperidone improve hyperacusia in children with autism? ( Ghanizadeh, A, 2009) |
| "The risperidone was started at 0." | 5.30 | Risperidone and explosive aggressive autism. ( Barnhill, LJ; Horrigan, JP, 1997) |
| "In this randomized, double-blind, placebo-controlled, parallel-group 10-week clinical trial, 70 drug-free children aged 4 to 12 years old with diagnosis of autistic disorder based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, who had an Aberrant Behavior Checklist-Community (ABC-C) scale irritability subscale score of ≥12, were equally randomized to receive either simvastatin (20-40 mg/day) or placebo as an adjunct to risperidone (1-2 mg/day) whereas administration of both drugs was started simultaneously from baseline." | 5.27 | Simvastatin as an Adjunctive Therapy to Risperidone in Treatment of Autism: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. ( Akhondzadeh, S; Karkhaneh-Yousefi, MA; Khezri, R; Moazen-Zadeh, E; Mohammadi, MR; Shirzad, F, 2018) |
| "This study aimed at investigating the efficacy and tolerability of l-carnosine as an add-on to risperidone in the management of children with autism." | 5.27 | l-Carnosine As an Adjunctive Therapy to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. ( Afarideh, M; Akhondzadeh, S; Ghajar, A; Hajizadeh-Zaker, R; Mesgarpour, B; Mohammadi, MR, 2018) |
| "Risperidone is a common psychopharmacological treatment for irritability in autism spectrum disorder (ASD)." | 5.22 | Initial severity and efficacy of risperidone in autism: Results from the RUPP trial. ( Furukawa, TA; Goldberg, Y; Kodesh, A; Kolevzon, A; Leucht, S; Levine, SZ; Reichenberg, A, 2016) |
| "This is an investigation of minocycline efficacy and safety as an adjuvant to risperidone in management of children with autism." | 5.22 | Minocycline as Adjunctive Treatment to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind Placebo-Controlled Trial. ( Akhondzadeh, S; Alikhani, R; Ghaleiha, A; Hamedi, M; Kazemi, MR; Keshavarzi, Z; Mohammadi, MR; Mohammadinejad, P; Shahriari, M; Zeinoddini, A, 2016) |
| "This clinical trial supports that low dose buspirone plus risperidone is more effective than risperidone plus placebo for treating irritability in individuals with autism." | 5.20 | A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism. ( Ayoobzadehshirazi, A; Ghanizadeh, A, 2015) |
| "To assess the safety and efficacy of pioglitazone added to risperidone in the treatment of irritability in autistic disorder (AD), we conducted this study." | 5.20 | A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: Effects on aberrant behavior in children with autism. ( Akhondzadeh, S; Farokhnia, M; Ghaleiha, A; Mohammadi, MR; Nikoo, M; Rasa, SM, 2015) |
| "Risperidone has demonstrated efficacy for acute (8 week) and intermediate length (6 month) management of severe irritability and aggression in children and adolescents with autism." | 5.20 | Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial. ( Aman, M; Arnold, LE; Ghuman, J; Grados, M; Hellings, J; Hollway, JA; McCracken, J; McDougle, CJ; Nagaraja, HN; Posey, DJ; Rettiganti, M; Scahill, L; Shah, B; Swiezy, NB; Tierney, E; Vitiello, B, 2015) |
| "Aripiprazole and risperidone are the only FDA approved medications for treating irritability in autistic disorder, however there are no head-to-head data comparing these agents." | 5.19 | A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. ( Berk, M; Ghanizadeh, A; Sahraeizadeh, A, 2014) |
| "Two cytokines, eotaxin and MCP-1, which have previously been identified as abnormally elevated in children with autism, decreased during treatment with risperidone." | 5.19 | Change in plasma cytokine levels during risperidone treatment in children with autism. ( Ashwood, P; Bent, S; Careaga, M; Choi, JE; Hendren, RL; Widjaja, F, 2014) |
| "Riluzole add-on therapy shows several therapeutic outcomes, particularly for improving irritability, in children with autism." | 5.17 | Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial. ( Akhondzadeh, S; Ashrafi, M; Farokhnia, M; Ghaleiha, A; Hassanzadeh, E; Modabbernia, A; Mohammadi, E; Mohammadi, MR; Yekehtaz, H, 2013) |
| "The purpose of this study was to evaluate the long-term safety and efficacy of risperidone in treating irritability and related behaviors in children and adolescents with autistic disorders." | 5.17 | An open-label extension study of the safety and efficacy of risperidone in children and adolescents with autistic disorder. ( Hough, D; Karcher, K; Kent, JM; Pandina, G; Singh, J, 2013) |
| "In a 10-week randomized double-blind placebo-controlled study, 40 outpatient children with a Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision clinical diagnosis of autism were randomly allocated to celecoxib plus risperidone or placebo plus risperidone." | 5.17 | Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. ( Akhondzadeh, S; Asadabadi, M; Ashrafi, M; Forghani, S; Ghanizadeh, A; Hassanzadeh, E; Modabbernia, A; Mohammadi, MR, 2013) |
| "Efficacy and safety of 2 risperidone doses were evaluated in children and adolescents with autism." | 5.17 | Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study. ( Aman, M; Hough, D; Karcher, K; Kent, JM; Kushner, S; Ness, S; Ning, X; Singh, J, 2013) |
| "Risperidone has been shown to improve serious behavioral problems in children with autism." | 5.15 | Risperidone-related improvement of irritability in children with autism is not associated with changes in serum of epidermal growth factor and interleukin-13. ( Aman, MG; Arnold, LE; Bothwell, AL; Chae, W; Hoekstra, PJ; Katsovich, L; Kawikova, I; Leckman, JF; McCracken, JT; McDougle, CJ; Scahill, L; Tierney, E; Tobiasova, Z; van der Lingen, KH; Vitiello, B; Volkmar, F; Zhang, Y, 2011) |
| "The results suggest that combination of atypical antipsychotic medications and pentoxifylline might have synergistic effects in treatment of behavioral problems of children with autism." | 5.14 | Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. ( Akhondzadeh, S; Fallah, J; Forghani, S; Ghanizadeh, A; Imani, R; Mohammadi, M; Mohammadi, MR; Mohebbi-Rasa, S; Raznahan, M; Rezazadeh, SA; Salehi, B, 2010) |
| " The present study assessed the effects of topiramate plus risperidone in the treatment of autistic disorder." | 5.14 | Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. ( Akhondzadeh, S; Ghanizadeh, A; Mohammadi, MR; Rezaei, V; Rezazadeh, SA; Sahraian, A; Tabrizi, M, 2010) |
| "The objective of this research was to explore the effects of risperidone on cognitive processes in children with autism and irritable behavior." | 5.13 | Cognitive effects of risperidone in children with autism and irritable behavior. ( Aman, MG; Arnold, LE; Cronin, P; Gavaletz, A; Ghuman, JK; Hollway, JA; Koenig, K; McCracken, JT; McDougle, CJ; Posey, DJ; Ritz, L; Scahill, L; Swiezy, N; Tierney, E; Vitiello, B; Wheeler, C, 2008) |
| " Therefore, it was of interest to assess the efficacy of piracetam, a positive modulator of AMPA-sensitive glutamate receptors in autistic disorder." | 5.13 | A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder. ( Akhondzadeh, S; Ghelichnia, HA; Mohammadi, M; Mohammadi, MR; Nouroozinejad, GH; Shabstari, OL; Tajdar, H, 2008) |
| "The aim of the study was to investigate safety, efficacy and tolerability of risperidone in comparison with haloperidol in the long-term treatment of autistic disorder." | 5.13 | Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. An open label maintenance study. ( Baykara, A; Baykara, B; Dirik, E; Emiroglu, FN; Gencer, O; Miral, S, 2008) |
| "The aim of the study was to compare safety, efficacy and tolerability of risperidone with haloperidol in the treatment of Autistic Disorder (AD)." | 5.13 | Risperidone versus haloperidol in children and adolescents with AD : a randomized, controlled, double-blind trial. ( Baykara, A; Baykara, B; Dirik, E; Gencer, O; Inal-Emiroglu, FN; Miral, S, 2008) |
| "We report on an open-label, naturalistic study using risperidone to treat disruptive behaviors and self-injury in children with Down syndrome, severe intellectual disability, and comorbid autism spectrum disorders (DS+ASDs)." | 5.13 | Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: a naturalistic study. ( Capone, GT; Goyal, P; Grados, M; Kammann, H; Smith, B, 2008) |
| "There are several studies investigating the effects of risperidone on autism, but many of these studies are contradictory or inconclusive." | 5.12 | Effects of Risperidone in Autistic Children and Young Adults: A Systematic Review and Meta-Analysis. ( Alves, BC; Belo, VS; Chaves, VE; Duarte-Almeida, JM; Galduróz, JCF; Mano-Sousa, BJ; Pedrosa, AM, 2021) |
| " The aim of this study was to investigate the phenomenology of SIB in a group of children with autistic disorder, and to test whether treatment with risperidone might reduce it." | 5.12 | Self injurious behavior in autism: clinical aspects and treatment with risperidone. ( Canitano, R, 2006) |
| "To evaluate the impact of risperidone on adaptive behavior in children with autistic disorder who have serious behavior problems and to examine different methods of scoring the Vineland Adaptive Behavior Scales to measure change." | 5.12 | Risperidone and adaptive behavior in children with autism. ( Aman, MG; Arnold, LE; Cicchetti, D; Cronin, P; Ghuman, J; Hollway, J; McCracken, JT; McDougle, CJ; Posey, DJ; Ritz, L; Scahill, L; Sparrow, S; Swiezy, NB; Tierney, E; Vitiello, B; Wheeler, C; Williams, SK, 2006) |
| "The effects of short- and long-term risperidone treatment on serum prolactin were assessed in children and adolescents with autism." | 5.12 | Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. ( Aman, MG; Anderson, GM; Arnold, LE; Katsovich, L; Martin, A; McCracken, JT; McDougle, CJ; Posey, DJ; Scahill, L; Shah, B; Tierney, E; Vitiello, B, 2007) |
| "Some open-label studies suggest that risperidone can be useful in the treatment of certain target symptoms in children with autism." | 5.12 | Risperidone in children with autism: randomized, placebo-controlled, double-blind study. ( Malhi, P; Nagaraj, R; Singhi, P, 2006) |
| "Subgroup analysis of children (5-12 years) with autism enrolled in an 8-week, double-blind, placebo-controlled trial of risperidone for pervasive developmental disorders." | 5.12 | Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. ( Bossie, CA; Dunbar, F; Pandina, GJ; Youssef, E; Zhu, Y, 2007) |
| "Parents of 101 children with autism who had participated in a multi-site 8-week double-blind clinical trial of risperidone were given a questionnaire at the end to elicit their perceptions of the appropriateness and acceptability of clinical trial procedures." | 5.12 | Parent satisfaction in a multi-site acute trial of risperidone in children with autism: a social validity study. ( Aman, M; Arnold, LE; Martin, A; McCracken, J; McDougle, C; Pappas, K; Posey, D; Scahill, L; Shah, B; Stout, D; Tierney, E; Vitiello, B; Wheeler, C, 2007) |
| "Risperidone may be effective in improving tantrums, aggression, or self-injurious behaviour in children with autism, but often leads to weight gain." | 5.12 | Dietary status and impact of risperidone on nutritional balance in children with autism: a pilot study. ( Aman, MG; Bozzolo, D; Eugene Arnold, L; Lindsay, RL; McCracken, JT; McDougle, CJ; Pachler, M; Posey, DJ; Scahill, L; Tierney, E; Vitiello, B, 2006) |
| "The aim of the present study was to evaluate the effectiveness and tolerability of risperidone in children with autistic disorder and to examine the correlation between plasma levels of risperidone and its active metabolite 9-hydroxyrisperidone (9-OH-risperidone) and the clinical response." | 5.11 | Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. ( Calamoneri, F; D'Arrigo, C; Gagliano, A; Germanò, E; Impallomeni, C; Pustorino, G; Spina, E, 2004) |
| "Weight change was measured for 63 children and adolescents with autism treated with risperidone for 6 months." | 5.11 | Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. ( Aman, M; Anderson, GM; Arnold, LE; Chuang, S; Martin, A; McCracken, J; McDougle, CJ; Scahill, L; Tierney, E; Vitiello, B, 2004) |
| "To investigate the efficacy and safety of risperidone for the treatment of disruptive behavioral symptoms in children with autism and other pervasive developmental disorders (PDD)." | 5.11 | Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. ( Carroll, A; Dunbar, F; Orlik, H; Schulz, M; Shea, S; Smith, I; Turgay, A, 2004) |
| "Risperidone has been found efficacious for decreasing severe tantrums, aggression, and self-injurious behavior in children and adolescents with autistic disorder (autism)." | 5.11 | Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. ( Aman, MG; Arnold, LE; Chuang, SZ; Davies, M; Ghuman, JK; Gonzalez, NM; Hollway, J; Koenig, K; Martin, A; McCracken, JT; McDougle, CJ; McGough, JJ; Posey, DJ; Ritz, L; Scahill, L; Shah, B; Swiezy, NB; Tierney, E; Vitiello, B, 2005) |
| "Risperidone is effective for short-term treatment of aggression, temper outbursts, and self-injurious behavior in children with autism." | 5.11 | Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. ( , 2005) |
| "The short-term benefit of risperidone in ameliorating severe disruptive behavior in pediatric patients with autism spectrum disorders is well established; however, only one placebo-controlled, long-term study of efficacy is available." | 5.11 | Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. ( Buitelaar, JK; Hoekstra, PJ; Ketelaars, CE; Lahuis, BE; Minderaa, RB; Scahill, L; Steenhuis, MP; Troost, PW; van Engeland, H, 2005) |
| " The blindness of clinical evaluators and parents was examined in a clinical trial of risperidone in autism." | 5.11 | Assessment of the integrity of study blindness in a pediatric clinical trial of risperidone. ( Aman, M; Arnold, LE; Davies, M; Koenig, K; McCracken, JT; McDougle, CJ; Posey, DJ; Scahill, L; Swiezy, NB; Tierney, E; Vitiello, B, 2005) |
| "We conducted a multisite, randomized, double-blind trial of risperidone as compared with placebo for the treatment of autistic disorder accompanied by severe tantrums, aggression, or self-injurious behavior in children 5 to 17 years old." | 5.10 | Risperidone in children with autism and serious behavioral problems. ( Aman, MG; Arnold, LE; Carroll, D; Cronin, P; Davies, M; Ghuman, J; Gonzalez, NM; Grados, M; Hollway, J; Hong, D; Koenig, K; Kohn, A; Lancor, A; Lindsay, R; Martin, A; McCracken, JT; McDougle, CJ; McGough, J; McMahon, D; Nash, P; Posey, D; Ritz, L; Robinson, J; Scahill, L; Shah, B; Swiezy, N; Tierney, E; Vitiello, B; Volkmar, F, 2002) |
| "The atypical antipsychotic medication risperidone was evaluated using a double-blind, placebo-controlled design in the treatment of destructive behavior in two individuals with autism." | 5.10 | Use of functional analysis methodology in the evaluation of medication effects. ( Crosland, KA; Hellings, JA; Lindauer, SE; Schroeder, SR; Valdovinos, MG; Zarcone, JR; Zarcone, TJ, 2003) |
| "In the Research Units on Pediatric Psychopharmacology (RUPP) Autism Network 8-week double-blind trial of risperidone versus placebo, the chief concerns of parents were collected at 0, 4, and 8 weeks (endpoint), in addition to standardized primary measures." | 5.10 | Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. ( Aman, MG; Arnold, LE; Chuang, S; Cronin, P; Davies, M; Gonzalez, NM; Hollway, J; Koenig, K; Kohn, AE; McDougle, C; McMahon, DJ; Scahill, L; Shah, B; Tierney, E; Vitiello, B, 2003) |
| "Atypical neuroleptics, including risperidone, are used to treat children with autism, despite limited efficacy and safety data." | 5.10 | Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. ( Choudhury, MS; Delaney, MA; Gifford, C; Maislin, G; Malone, RP, 2002) |
| ", weight gain, liver function, extrapyramidal side effects, and seizures) and efficacy of the long-term use of risperidone in children and adolescents and to ascertain the effects of drug withdrawal in a semi-naturalistic prospective, subjects with autism or pervasive developmental disorders not otherwise specified (PDDNOS) were treated with risperidone for 6 months after which parents were given the option of continuing for a further 6 months (final assessment at 12 months)." | 5.09 | Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. ( Cianchetti, C; Di Martino, A; Muglia, P; Zuddas, A, 2000) |
| "As part of an ongoing, prospective, ABA design, double-blind crossover study of risperidone versus placebo for the treatment of aggressive, destructive and self-injurious behavior in persons aged 6-65 years with mental retardation (MR) and autism, we measured the weight of 19 subjects at each study visit." | 5.09 | Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. ( Crandall, K; Hellings, JA; Schroeder, SR; Wallace, D; Zarcone, JR, 2001) |
| "To describe the methodological challenges and decisions made in developing a multisite, controlled study of risperidone in children and adolescents with autism." | 5.09 | Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism. ( Aman, M; Arnold, LE; Cronin, P; Davies, M; Ghuman, J; Gonzalez, N; Koenig, K; Lindsay, R; Martin, A; McCracken, J; McDougle, CJ; McGough, J; Posey, DJ; Ritz, L; Scahill, L; Swiezy, N; Tierney, E; Vitiello, B; Volkmar, F, 2001) |
| "These results suggest that risperidone may be safe and leads to improvements in several behavioral symptoms in young children with autism." | 5.08 | An open trial of risperidone in young autistic children. ( Awad, G; Nicolson, R; Sloman, L, 1998) |
| "Risperidone is more effective than placebo in the short-term treatment of symptoms of autism in adults." | 5.08 | A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. ( Carlson, DC; Cohen, DJ; Holmes, JP; McDougle, CJ; Pelton, GH; Price, LH, 1998) |
| "The pharmacokinetics, pharmacodynamics, safety and efficacy data on aripiprazole for the treatment of irritability associated with autism are discussed." | 4.87 | Aripiprazole for the treatment of irritability associated with autism. ( Aman, MG; Farmer, CA, 2011) |
| "To determine the efficacy and safety of risperidone for people with autism spectrum disorder." | 4.84 | Risperidone for autism spectrum disorder. ( Aref-Adib, M; Coren, E; Jesner, OS, 2007) |
| "To review the clinical trials investigating the efficacy and safety of risperidone in the treatment of children with autism spectrum disorder (ASD)." | 4.83 | Role of risperidone in children with autism spectrum disorder. ( Chavez, B; Chavez-Brown, M; Rey, JA, 2006) |
| "This article has reviewed the background and rationale for the choice of risperidone as the first drug to be studied by the RUPP Autism Network." | 4.80 | Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone. ( Aman, MG; Arnold, LE; Cronin, P; Freeman, BJ; Martin, A; McCracken, JT; McDougle, CJ; McGough, JJ; Posey, DJ; Riddle, MA; Ritz, L; Scahill, L; Swiezy, NB; Tierney, E; Vitiello, B; Volkmar, FR; Votolato, NA; Walson, P, 2000) |
| "Risperidone is the first antipsychotic to be approved by Food and Drug Administration (FDA) for treating autism spectrum disorder (ASD)." | 4.31 | The comparative effectiveness of metformin and risperidone in a rat model of valproic acid-induced autism, Potential role for enhanced autophagy. ( Ashour, RH; Atia, AA; Rahman, KM; Ramadan, NM; Zaki, MM, 2023) |
| " Here, authors report on a challenging case of low-functioning ASD child with comorbid ARFID and misophonia that responded favorably to a low-dose risperidone." | 4.12 | Low-Dose Risperidone for an Autistic Child with Comorbid ARFID and Misophonia. ( Abuzeid, MY; Al-Humoud, AM; Elsori, D; Naguy, A; Pridmore, S; Singh, A, 2022) |
| " Diagnosis of autism was based on DSM-V criteria and the severity degree was measured by ABC-C checklists at base line and after 8 weeks of treatment with risperidone." | 3.85 | DRD3 Ser9Gly Polymorphism and Its Influence on Risperidone Response in Autistic Children. ( Firouzabadi, N; Nazariat, A; Zomorrodian, K, 2017) |
| "Risperidone treatment disturbed glucose homeostasis and endocrine regulation (particularly leptin) in children and adolescents with ASDs, in a dose- and duration-dependent manner, being suggestive of leptin and insulin resistance mechanisms." | 3.85 | Impact of risperidone on leptin and insulin in children and adolescents with autistic spectrum disorders. ( Hongkaew, Y; Intachak, B; Kroll, MH; Limsila, P; Ngamsamut, N; Puangpetch, A; Srisawasdi, P; Sukasem, C; Vanavanan, S; Vanwong, N, 2017) |
| "Risperidone, an atypical antipsychotic drug, is one of the most frequently used atypical neuroleptic drugs for the treatment of symptoms of behavioral disorders seen in autism." | 3.83 | Multifocal atrial tachycardia caused by risperidone. ( Adaletli, H; Akdeniz, C; Oner, T, 2016) |
| "We report several cases in which patients with autistic disorder with mental retardation who received risperidone experienced urinary incontinence." | 3.80 | Risperidone-associated urinary incontinence in patients with autistic disorder with mental retardation. ( Imasaka, Y; Iwata, K; Kumazaki, H; Mimura, M; Tomoda, A; Watanabe, K, 2014) |
| "Risperidone's beneficial effect on aggression and other elements of adaptive functioning were not necessarily accompanied by reduction in core ASD symptoms, as serially assessed by the same caregivers who reported improvement in their children." | 3.80 | Lack of effect of risperidone on core autistic symptoms: data from a longitudinal study. ( Constantino, JN; Marrus, N; Randall, F; Underwood-Riordan, H; Zhang, Y, 2014) |
| "Assessment of autistic disorder (autism) symptoms, primary and secondary, poses more challenging problems than ordinarily found in multisite randomized clinical trial (RCT) assessments." | 3.79 | Assessment in multisite randomized clinical trials of patients with autistic disorder: the Autism RUPP Network. Research Units on Pediatric Psychopharmacology. ( Aman, MG; Arnold, LE; Asarnow, R; Bell-Bradshaw, F; Collier-Crespin, A; Freeman, BJ; Gates-Ulanet, P; Klin, A; Martin, A; McCracken, JT; McDougle, CJ; McGough, JJ; Posey, DJ; Ritz, L; Scahill, L; Swiezy, NB; Tierney, E; Vitiello, B; Volkmar, F, 2000) |
| "To study the effect of risperidone treatment on behavioral disorders in children with autism." | 3.77 | [Treatment of behavioral disorders by risperidone in children with autism]. ( Huang, F; Liang, QQ; Qin, XT; Wei, BY, 2011) |
| "2 in favor of risperidone on the main outcome measure in an 8-week double-blind, placebo-controlled trial for irritability in autistic disorder." | 3.76 | Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability. ( Aman, MG; Arnold, LE; Chuang, S; Davies, M; DiSilvestro, R; Farmer, C; Kraemer, HC; McCracken, J; McDougle, CJ; Posey, DJ; Scahill, L; Swiezy, NB; Vitiello, B; Witwer, A, 2010) |
| "Two children aged 11 and 10 years, diagnosed with autism and mental retardation, have developed new-onset diurnal and nocturnal enuresis respectively on their first and second weeks of risperidone monotherapy (1." | 3.74 | Risperidone-induced enuresis in two children with autistic disorder. ( Hergüner, S; Mukaddes, NM, 2007) |
| "Parents of 101 children (age 5-17 years) with autism participating in a placebo-controlled trial of risperidone were given a questionnaire at the end of the study." | 3.73 | Research knowledge among parents of children participating in a randomized clinical trial. ( Aman, MG; Arnold, LE; Davies, M; McCracken, JT; McDougle, CJ; Scahill, L; Tierney, E; Vitiello, B, 2005) |
| "This report describes the use of risperidone in the treatment of two very young children with autistic disorder, a 29-month-old boy and a 23-month-old boy, respectively." | 3.70 | Risperidone in the treatment of two very young children with autism. ( McDougle, CJ; Posey, DJ; Walsh, KH; Wilson, GA, 1999) |
| "The etiology of autism is hypothesized to include both biological and environmental factors (Watts, 2008)." | 3.01 | Autism Spectrum Disorder and Complementary-Integrative Medicine. ( Arnold, LE; Hendren, RL; Simkin, DR; Vandana, P, 2023) |
| "Patients were assessed using childhood autism rating scale (CARS), Gilliam autism rating scale-second edition (GARS-II), and clinical global impression (CGI) at the baseline, as well as 6 and 12 months after intervention." | 3.01 | Intrathecal autologous bone marrow stem cell therapy in children with autism: A randomized controlled trial. ( Fayyazi Bordbar, MR; Ghasemi, A; Moharari, F; Nahidi, M; Pouryousof, HR; Sharifzadeh, N; Soltanifar, A; Talaei, A; Tavakol Afshari, J; Ziaee, M, 2021) |
| "Seventy children (aged 4-12 years) with autism and moderate to severe symptoms of irritability were randomly assigned to two treatment regimens." | 2.87 | Palmitoylethanolamide as adjunctive therapy for autism: Efficacy and safety results from a randomized controlled trial. ( Akhondzadeh, S; Alavi, K; Hosseini, M; Khalaj, M; Laksari, FY; Mohammadi, MR; Saghazadeh, A; Shalbafan, MR; Shirazi, E; Shooshtari, MH, 2018) |
| "Children with autism were randomly allocated to risperidone plus memantine or placebo plus risperidone for a 10-wk, double-blind, placebo-controlled study." | 2.78 | Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. ( Akhondzadeh, S; Asadabadi, M; Ghaleiha, A; Hajiaghaee, R; Hassanzadeh, E; Mohammadi, MR; Shahei, M; Tabrizi, M, 2013) |
| "Risperidone has shown safety and efficacy for aggressive and destructive behaviors in short-term studies." | 2.72 | A crossover study of risperidone in children, adolescents and adults with mental retardation. ( Fleming, KK; Hellings, JA; Marquis, JG; Reese, RM; Schroeder, SR; Valdovinos, MG; Zarcone, JR, 2006) |
| "Preschool children tolerated low-dose risperidone well with no serious adverse effects observed over a 6-month treatment period." | 2.72 | Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. ( Belden, A; Heffelfinger, A; Luby, J; Mrakotsky, C; Spitznagel, E; Stalets, MM; Williams, M, 2006) |
| "Treatment-emergent adverse events (AEs) were monitored during an 8-week, double-blind, placebo-controlled trial of risperidone (0." | 2.71 | Acute and long-term safety and tolerability of risperidone in children with autism. ( Aman, MG; Arnold, LE; Chuang, S; Davies, M; Ghuman, JK; Gonzalez, NM; Koenig, K; Lindsay, RL; Martin, A; McCracken, JT; McDougle, CJ; McGough, J; Nash, PL; Posey, DJ; Ritz, L; Scahill, L; Shah, B; Swiezy, NB; Tierney, E; Vitiello, B, 2005) |
| "Risperidone has been described as having salutary effects as an adjunctive pharmacotherapy in adult and pediatric patients with AD." | 2.68 | An open clinical trial of risperidone monotherapy in young children with autistic disorder. ( Findling, RL; Maxwell, K; Wiznitzer, M, 1997) |
| "Autism spectrum disorder is characterized by difficulty with social communication and restricted, repetitive patterns of behavior, interest, or activities." | 2.53 | Autism Spectrum Disorder: Primary Care Principles. ( Sanchack, KE; Thomas, CA, 2016) |
| "Oral risperidone treatment was better than placebo treatment in reducing irritability and other behavioral symptoms associated with autistic disorder in children and adolescents in two well designed short-term trials, with these benefits maintained in those receiving risperidone for up to 6 months." | 2.44 | Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents. ( Dhillon, S; Scott, LJ, 2007) |
| "Many theories about the causes of autism have been suggested, including the MMR vaccine." | 2.43 | Autistic spectrum disorders 2: diagnosis and management. ( Chowdhury, U; Cork, C; Jones, A, 2006) |
| "Autistic disorder (autism) is a neuropsychiatric syndrome characterized by marked deficits in reciprocal social relatedness, communication impairment and a narrow range of interests and/or repetitive behaviors." | 2.41 | Risperidone: a potential treatment for autism. ( McDougle, CJ; Posey, DJ, 2002) |
| "Despite the fact that psychiatric illness in the pre-adult era is not rare, few controlled clinical trials have examined the short-term safety and efficacy of these agents in youths with psychosis." | 2.39 | Antipsychotic medications in children and adolescents. ( Findling, RL; Grcevich, SJ; Lopez, I; Schulz, SC, 1996) |
| "Autism spectrum disorder is a diagnosis that includes significant social communication deficits/delays along with restricted patterns of interests and behaviors." | 1.43 | Treatment of Autism Spectrum Disorder in Children and Adolescents. ( DeFilippis, M; Wagner, KD, 2016) |
| "Risperidone also has multiple receptor targets in which only a subset may be procognitive and others induce cognitive impairment." | 1.40 | Risperidone and the 5-HT2A receptor antagonist M100907 improve probabilistic reversal learning in BTBR T + tf/J mice. ( Amodeo, DA; Jones, JH; Ragozzino, ME; Sweeney, JA, 2014) |
| "Autism is a pervasive developmental disorder characterised by impairment in social interaction and communication, with unusual behavior." | 1.37 | The treatment of autistic children with risperidone. ( Curković, M; Dodig-Curković, K; Radić, J; Radić, M, 2011) |
| "Risperidone have been reported to commonly lead to asymptomatic elevation of liver enzymes in adult population, and recently in children and adolescents." | 1.37 | Risperidone rechallenge for marked liver function test abnormalities in an autistic child. ( Copur, M; Erdogan, A, 2011) |
| "Many of children with autism have hyperacusia, an increased sensation to sound." | 1.35 | Does risperidone improve hyperacusia in children with autism? ( Ghanizadeh, A, 2009) |
| "Citalopram was the most preferred antidepressant and Carbamazepine, the most preferred mood stabilizer/antiepileptic." | 1.35 | Use of medication for the management of behavior problems among adults with intellectual disabilities: a clinicians' consensus survey. ( Deb, S; Unwin, GL, 2008) |
| "Treatment with risperidone 0." | 1.31 | Risperidone in the treatment of autistic Thai children under 4 years of age. ( Boon-Yasidhi, V; Soising, L; Suwanwattana, C; Tarugsa, J, 2002) |
| "Outcome measures were the Childhood Autism Rating Scale, the Children's Psychiatric Rating Scale, Clinical Global Impression (improvement score), and the Children's Global Assessment of Functioning." | 1.31 | Risperidone monotherapy in preschool children with pervasive developmental disorders. ( Cosenza, A; De Vito, G; Masi, G; Mucci, M, 2001) |
| "Risperidone is an atypical antipsychotic used in the treatment of several psychiatric disorders in both children and adults." | 1.31 | Side-effects of risperidone therapy mimicking cerebrospinal fluid shunt malfunction: implications for clinical monitoring and management. ( Edwards, RJ; Pople, IK, 2002) |
| "The risperidone was started at 0." | 1.30 | Risperidone and explosive aggressive autism. ( Barnhill, LJ; Horrigan, JP, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 16 (9.76) | 18.2507 |
| 2000's | 80 (48.78) | 29.6817 |
| 2010's | 56 (34.15) | 24.3611 |
| 2020's | 12 (7.32) | 2.80 |
| Authors | Studies |
|---|---|
| Soltani Kouhbanani, S | 1 |
| Khosrorad, R | 1 |
| Zarenezhad, S | 1 |
| Arabi, SM | 1 |
| Elnahas, EM | 2 |
| Abuelezz, SA | 1 |
| Mohamad, MI | 1 |
| Nabil, MM | 1 |
| Abdelraouf, SM | 1 |
| Bahaa, N | 1 |
| Hassan, GAM | 1 |
| Aboul-Fotouh, S | 2 |
| Naguy, A | 2 |
| Al-Humoud, AM | 1 |
| Pridmore, S | 2 |
| Abuzeid, MY | 1 |
| Singh, A | 1 |
| Elsori, D | 1 |
| Jamali, MA | 1 |
| Hasan, AE | 1 |
| Alamiri, B | 1 |
| Atia, AA | 1 |
| Ashour, RH | 1 |
| Zaki, MM | 1 |
| Rahman, KM | 1 |
| Ramadan, NM | 1 |
| Vandana, P | 1 |
| Simkin, DR | 1 |
| Hendren, RL | 3 |
| Arnold, LE | 20 |
| Habib, MZ | 1 |
| Aboul-Ela, YM | 1 |
| Ebeid, MA | 1 |
| Tarek, M | 1 |
| Sadek, DR | 1 |
| Negm, EA | 1 |
| Abdelhakam, DA | 1 |
| Mano-Sousa, BJ | 1 |
| Pedrosa, AM | 1 |
| Alves, BC | 1 |
| Galduróz, JCF | 1 |
| Belo, VS | 1 |
| Chaves, VE | 1 |
| Duarte-Almeida, JM | 1 |
| Amini, A | 1 |
| Namvarpour, Z | 1 |
| Namvarpour, M | 1 |
| Raoofi, A | 1 |
| Güneş, H | 1 |
| Acıpayam, C | 1 |
| Akgüngör, F | 1 |
| Kütükçü, M | 1 |
| Sharifzadeh, N | 1 |
| Ghasemi, A | 1 |
| Tavakol Afshari, J | 1 |
| Moharari, F | 1 |
| Soltanifar, A | 1 |
| Talaei, A | 1 |
| Pouryousof, HR | 1 |
| Nahidi, M | 1 |
| Fayyazi Bordbar, MR | 1 |
| Ziaee, M | 1 |
| Sun, CK | 1 |
| Cheng, YS | 1 |
| Hung, KC | 1 |
| Nuntamool, N | 1 |
| Ngamsamut, N | 2 |
| Vanwong, N | 2 |
| Puangpetch, A | 2 |
| Chamnanphon, M | 1 |
| Hongkaew, Y | 2 |
| Limsila, P | 2 |
| Suthisisang, C | 1 |
| Wilffert, B | 1 |
| Sukasem, C | 2 |
| Moazen-Zadeh, E | 1 |
| Shirzad, F | 1 |
| Karkhaneh-Yousefi, MA | 1 |
| Khezri, R | 1 |
| Mohammadi, MR | 12 |
| Akhondzadeh, S | 12 |
| Hajizadeh-Zaker, R | 1 |
| Ghajar, A | 1 |
| Mesgarpour, B | 1 |
| Afarideh, M | 1 |
| Firouzabadi, N | 1 |
| Nazariat, A | 1 |
| Zomorrodian, K | 1 |
| Khalaj, M | 1 |
| Saghazadeh, A | 1 |
| Shirazi, E | 1 |
| Shalbafan, MR | 1 |
| Alavi, K | 1 |
| Shooshtari, MH | 1 |
| Laksari, FY | 1 |
| Hosseini, M | 1 |
| Hussain, K | 1 |
| Gkini, MA | 1 |
| Taylor, R | 1 |
| Shinhmar, S | 1 |
| Bewley, A | 1 |
| Kidd, V | 1 |
| Pradhan, T | 1 |
| Hardan, A | 1 |
| Bachmann, CJ | 1 |
| Manthey, T | 1 |
| Kamp-Becker, I | 1 |
| Glaeske, G | 1 |
| Hoffmann, F | 1 |
| Ghanizadeh, A | 7 |
| Sahraeizadeh, A | 1 |
| Berk, M | 1 |
| Ghaleiha, A | 5 |
| Mohammadi, E | 1 |
| Farokhnia, M | 3 |
| Modabbernia, A | 2 |
| Yekehtaz, H | 2 |
| Ashrafi, M | 2 |
| Hassanzadeh, E | 3 |
| Moghimi-Sarani, E | 1 |
| Ghyasvand, M | 1 |
| Yadegari, N | 1 |
| Tabrizi, M | 3 |
| Hajiaghaee, R | 2 |
| Kent, JM | 2 |
| Hough, D | 2 |
| Singh, J | 2 |
| Karcher, K | 2 |
| Pandina, G | 1 |
| Baribeau, DA | 1 |
| Anagnostou, E | 1 |
| Adler, BA | 1 |
| Wink, LK | 1 |
| Early, M | 1 |
| Shaffer, R | 1 |
| Minshawi, N | 1 |
| McDougle, CJ | 25 |
| Erickson, CA | 2 |
| Choi, JE | 1 |
| Widjaja, F | 1 |
| Careaga, M | 1 |
| Bent, S | 2 |
| Ashwood, P | 1 |
| Amodeo, DA | 1 |
| Jones, JH | 1 |
| Sweeney, JA | 1 |
| Ragozzino, ME | 1 |
| Kumazaki, H | 1 |
| Watanabe, K | 1 |
| Imasaka, Y | 1 |
| Iwata, K | 1 |
| Tomoda, A | 1 |
| Mimura, M | 1 |
| Marrus, N | 1 |
| Underwood-Riordan, H | 1 |
| Randall, F | 1 |
| Zhang, Y | 2 |
| Constantino, JN | 1 |
| Ayoobzadehshirazi, A | 1 |
| Brosco, JP | 1 |
| Rasa, SM | 1 |
| Nikoo, M | 1 |
| Koplewicz, HS | 1 |
| Aman, M | 6 |
| Rettiganti, M | 1 |
| Nagaraja, HN | 1 |
| Hollway, JA | 3 |
| McCracken, J | 5 |
| Tierney, E | 18 |
| Scahill, L | 24 |
| Hellings, J | 1 |
| Posey, DJ | 15 |
| Swiezy, NB | 8 |
| Ghuman, J | 4 |
| Grados, M | 3 |
| Shah, B | 7 |
| Vitiello, B | 20 |
| Oner, T | 1 |
| Akdeniz, C | 1 |
| Adaletli, H | 1 |
| Levine, SZ | 1 |
| Kodesh, A | 1 |
| Goldberg, Y | 1 |
| Reichenberg, A | 1 |
| Furukawa, TA | 1 |
| Kolevzon, A | 1 |
| Leucht, S | 1 |
| Del Casale, A | 1 |
| Kotzalidis, GD | 1 |
| Sacco, M | 1 |
| Rapinesi, C | 1 |
| De Giorgi, R | 1 |
| Giardini, M | 1 |
| D'Andreagiovanni, M | 1 |
| Carlino, N | 1 |
| Brugnoli, R | 1 |
| Girardi, P | 1 |
| Alikhani, R | 1 |
| Kazemi, MR | 1 |
| Mohammadinejad, P | 1 |
| Zeinoddini, A | 1 |
| Hamedi, M | 1 |
| Shahriari, M | 1 |
| Keshavarzi, Z | 1 |
| Chen, F | 1 |
| Nikvarz, N | 1 |
| Alaghband-Rad, J | 1 |
| Tehrani-Doost, M | 1 |
| Alimadadi, A | 1 |
| Ghaeli, P | 1 |
| DeFilippis, M | 1 |
| Wagner, KD | 1 |
| Sanchack, KE | 1 |
| Thomas, CA | 1 |
| Srisawasdi, P | 1 |
| Vanavanan, S | 1 |
| Intachak, B | 1 |
| Kroll, MH | 1 |
| Stigler, KA | 2 |
| Aman, MG | 16 |
| McCracken, JT | 13 |
| Ritz, L | 8 |
| Gavaletz, A | 2 |
| Cronin, P | 6 |
| Swiezy, N | 3 |
| Wheeler, C | 3 |
| Koenig, K | 9 |
| Ghuman, JK | 3 |
| Fallah, J | 1 |
| Imani, R | 1 |
| Mohammadi, M | 2 |
| Salehi, B | 1 |
| Raznahan, M | 1 |
| Mohebbi-Rasa, S | 1 |
| Rezazadeh, SA | 2 |
| Forghani, S | 2 |
| Correia, CT | 1 |
| Almeida, JP | 1 |
| Santos, PE | 1 |
| Sequeira, AF | 1 |
| Marques, CE | 1 |
| Miguel, TS | 1 |
| Abreu, RL | 1 |
| Oliveira, GG | 1 |
| Vicente, AM | 1 |
| Ozdemir, DF | 1 |
| Karabacak, NI | 1 |
| Akkaş, B | 1 |
| Akdemir, O | 1 |
| Unal, F | 1 |
| Senol, S | 1 |
| Farmer, C | 1 |
| Kraemer, HC | 1 |
| Davies, M | 8 |
| Witwer, A | 1 |
| Chuang, S | 4 |
| DiSilvestro, R | 1 |
| Valdovinos, MG | 4 |
| Bailey, L | 1 |
| Taylor, SL | 1 |
| Rezaei, V | 1 |
| Sahraian, A | 1 |
| Chadman, KK | 1 |
| Hardan, AY | 1 |
| Fung, LK | 1 |
| Amin, H | 1 |
| Farmer, CA | 1 |
| Wei, BY | 1 |
| Huang, F | 1 |
| Qin, XT | 1 |
| Liang, QQ | 1 |
| Dodig-Curković, K | 1 |
| Curković, M | 1 |
| Radić, J | 1 |
| Radić, M | 1 |
| Copur, M | 1 |
| Erdogan, A | 1 |
| Tobiasova, Z | 1 |
| van der Lingen, KH | 1 |
| Leckman, JF | 1 |
| Chae, W | 1 |
| Katsovich, L | 2 |
| Hoekstra, PJ | 2 |
| Volkmar, F | 4 |
| Bothwell, AL | 1 |
| Kawikova, I | 1 |
| Cop, E | 1 |
| Oner, P | 1 |
| Oner, O | 1 |
| Nakamae, T | 1 |
| Johnson, C | 1 |
| Handen, B | 1 |
| Bearss, K | 1 |
| Dziura, J | 1 |
| Butter, E | 1 |
| Swiezy, NG | 1 |
| Sukhodolsky, DD | 1 |
| Lecavalier, L | 2 |
| Pozdol, SL | 1 |
| Nikolov, R | 2 |
| Korzekwa, P | 1 |
| Kohn, AE | 2 |
| Grinnon, S | 1 |
| Mulick, JA | 1 |
| Yu, S | 1 |
| Asadabadi, M | 2 |
| Gandal, MJ | 1 |
| Sisti, J | 1 |
| Klook, K | 1 |
| Ortinski, PI | 1 |
| Leitman, V | 1 |
| Liang, Y | 1 |
| Thieu, T | 1 |
| Anderson, R | 1 |
| Pierce, RC | 1 |
| Jonak, G | 1 |
| Gur, RE | 1 |
| Carlson, G | 1 |
| Siegel, SJ | 1 |
| Shahei, M | 1 |
| Eisenstein, M | 1 |
| Kushner, S | 1 |
| Ning, X | 1 |
| Ness, S | 1 |
| Bozkurt, H | 1 |
| Ayaydın, H | 1 |
| Adak, İ | 1 |
| Zoroğlu, SS | 1 |
| Rapin, I | 1 |
| McGough, J | 3 |
| Hong, D | 1 |
| Lindsay, R | 2 |
| Nash, P | 1 |
| Hollway, J | 4 |
| Posey, D | 2 |
| Kohn, A | 1 |
| Martin, A | 9 |
| Carroll, D | 1 |
| Lancor, A | 1 |
| Gonzalez, NM | 4 |
| Robinson, J | 1 |
| McMahon, D | 1 |
| Napolitano, DA | 2 |
| Zarcone, JR | 4 |
| Hellings, JA | 4 |
| Williams, DC | 2 |
| Schroeder, SR | 5 |
| Boon-Yasidhi, V | 1 |
| Tarugsa, J | 1 |
| Suwanwattana, C | 1 |
| Soising, L | 1 |
| Sandler, L | 1 |
| Valiquette, G | 1 |
| Munarriz, R | 1 |
| Bennett, L | 1 |
| Goldstein, I | 1 |
| Caicedo, C | 1 |
| Williams, SH | 1 |
| Yoo, JH | 1 |
| Peyton, RT | 1 |
| Baer, DM | 1 |
| Crosland, KA | 1 |
| Lindauer, SE | 1 |
| Zarcone, TJ | 1 |
| McDougle, C | 2 |
| McMahon, DJ | 1 |
| Masi, G | 3 |
| Cosenza, A | 3 |
| Mucci, M | 3 |
| Brovedani, P | 2 |
| Nishimura, M | 1 |
| Hashimoto, T | 1 |
| Miyazaki, M | 1 |
| Mori, K | 1 |
| Kuroda, Y | 1 |
| Kwon, H | 1 |
| Gagliano, A | 1 |
| Germanò, E | 1 |
| Pustorino, G | 1 |
| Impallomeni, C | 1 |
| D'Arrigo, C | 1 |
| Calamoneri, F | 1 |
| Spina, E | 1 |
| Anderson, GM | 2 |
| Shea, S | 1 |
| Turgay, A | 1 |
| Carroll, A | 1 |
| Schulz, M | 1 |
| Orlik, H | 1 |
| Smith, I | 1 |
| Dunbar, F | 2 |
| Stein, MT | 1 |
| Faber, S | 1 |
| Berger, SP | 1 |
| Kliman, G | 1 |
| Mukaddes, NM | 3 |
| Abali, O | 1 |
| Gurkan, K | 1 |
| Yang, P | 1 |
| Tsai, JH | 1 |
| Kastner, TA | 1 |
| Chuang, SZ | 1 |
| McGough, JJ | 3 |
| Bober, D | 1 |
| Sabzwari, U | 1 |
| Star, JE | 1 |
| Canitano, R | 1 |
| Troost, PW | 1 |
| Lahuis, BE | 1 |
| Steenhuis, MP | 1 |
| Ketelaars, CE | 1 |
| Buitelaar, JK | 1 |
| van Engeland, H | 1 |
| Minderaa, RB | 1 |
| Nash, PL | 1 |
| Lindsay, RL | 2 |
| Adetunji, B | 1 |
| Mathews, M | 1 |
| Osinowo, T | 1 |
| Williams, A | 1 |
| Reese, RM | 1 |
| Marquis, JG | 1 |
| Fleming, KK | 1 |
| Williams, SK | 1 |
| Cicchetti, D | 1 |
| Sparrow, S | 1 |
| Parr, J | 1 |
| Jones, A | 1 |
| Cork, C | 1 |
| Chowdhury, U | 1 |
| Feroz-Nainar, C | 2 |
| Roy, M | 2 |
| Selvaraj, P | 1 |
| Chavez, B | 1 |
| Chavez-Brown, M | 1 |
| Rey, JA | 1 |
| Jonker, J | 1 |
| Nagaraj, R | 1 |
| Singhi, P | 1 |
| Malhi, P | 1 |
| Pandina, GJ | 1 |
| Bossie, CA | 1 |
| Youssef, E | 1 |
| Zhu, Y | 1 |
| Luby, J | 1 |
| Mrakotsky, C | 1 |
| Stalets, MM | 1 |
| Belden, A | 1 |
| Heffelfinger, A | 1 |
| Williams, M | 1 |
| Spitznagel, E | 1 |
| Stout, D | 1 |
| Pappas, K | 1 |
| Eugene Arnold, L | 1 |
| Pachler, M | 2 |
| Bozzolo, D | 1 |
| Ivanov, I | 1 |
| Klein, M | 1 |
| Green, WH | 1 |
| Coffey, B | 1 |
| Jesner, OS | 1 |
| Aref-Adib, M | 1 |
| Coren, E | 1 |
| Hamilton, JD | 1 |
| Morgan, S | 1 |
| Taylor, E | 1 |
| Carr, JE | 1 |
| LeBlanc, LA | 1 |
| Sukhodolsky, DG | 1 |
| Gadow, KD | 1 |
| Williams White, S | 1 |
| Carroll, DH | 1 |
| Hergüner, S | 2 |
| Scott, LJ | 1 |
| Dhillon, S | 1 |
| Tajdar, H | 1 |
| Nouroozinejad, GH | 1 |
| Shabstari, OL | 1 |
| Ghelichnia, HA | 1 |
| Gencer, O | 2 |
| Emiroglu, FN | 1 |
| Miral, S | 2 |
| Baykara, B | 2 |
| Baykara, A | 2 |
| Dirik, E | 2 |
| Inal-Emiroglu, FN | 1 |
| Unwin, GL | 1 |
| Deb, S | 1 |
| Capone, GT | 1 |
| Goyal, P | 1 |
| Smith, B | 1 |
| Kammann, H | 1 |
| Malone, RP | 2 |
| Harvey, JA | 1 |
| Purdon, SE | 1 |
| Lit, W | 1 |
| Labelle, A | 1 |
| Jones, BD | 1 |
| Took, KJ | 1 |
| Buck, BJ | 1 |
| Fisman, S | 1 |
| Steele, M | 1 |
| Short, J | 1 |
| Byrne, T | 1 |
| Lavallee, C | 1 |
| Findling, RL | 2 |
| Grcevich, SJ | 1 |
| Lopez, I | 1 |
| Schulz, SC | 1 |
| Maxwell, K | 1 |
| Wiznitzer, M | 1 |
| Frischauf, E | 1 |
| Horrigan, JP | 1 |
| Barnhill, LJ | 1 |
| Demb, HB | 1 |
| Nicolson, R | 1 |
| Awad, G | 1 |
| Sloman, L | 1 |
| Schwam, JS | 1 |
| Klass, E | 1 |
| Alonso, C | 1 |
| Perry, R | 1 |
| Holmes, JP | 2 |
| Carlson, DC | 1 |
| Pelton, GH | 1 |
| Cohen, DJ | 1 |
| Price, LH | 1 |
| Leventhal, BL | 1 |
| Cook, EH | 1 |
| Lord, C | 1 |
| Doan, RJ | 1 |
| Dartnall, NA | 1 |
| Morgan, SN | 1 |
| Blatt, SD | 1 |
| Meguid, V | 1 |
| Church, CC | 1 |
| Botash, AS | 1 |
| Jean-Louis, F | 1 |
| Siripornsawan, MP | 1 |
| Weinberger, HL | 1 |
| Walsh, KH | 1 |
| Wilson, GA | 1 |
| Freeman, BJ | 2 |
| Riddle, MA | 1 |
| Volkmar, FR | 1 |
| Votolato, NA | 1 |
| Walson, P | 1 |
| Collier-Crespin, A | 1 |
| Asarnow, R | 1 |
| Bell-Bradshaw, F | 1 |
| Gates-Ulanet, P | 1 |
| Klin, A | 1 |
| Zuddas, A | 1 |
| Di Martino, A | 1 |
| Muglia, P | 1 |
| Cianchetti, C | 1 |
| Hunsinger, DM | 1 |
| Nguyen, T | 1 |
| Zebraski, SE | 1 |
| Raffa, RB | 1 |
| De Vito, G | 1 |
| Vercellino, F | 1 |
| Zanotto, E | 1 |
| Ravera, G | 1 |
| Veneselli, E | 1 |
| Mikhail, AG | 1 |
| King, BH | 1 |
| Crandall, K | 1 |
| Wallace, D | 1 |
| Maislin, G | 1 |
| Choudhury, MS | 1 |
| Gifford, C | 1 |
| Delaney, MA | 1 |
| Gonzalez, N | 1 |
| Edwards, RJ | 1 |
| Pople, IK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Risperidone in the Treatment of Children and Adolescents With Autistic Disorder: A Double-Blind, Placebo-Controlled Study of Efficacy and Safety, Followed by an Open-Label Extension Study of Safety[NCT00576732] | Phase 4 | 96 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Video Assisted Speech Technology to Enhance Functional Language Abilities in Individuals With Autism Spectrum Disorder[NCT04764539] | 6 participants (Actual) | Interventional | 2019-12-01 | Completed | |||
| Emotion Awareness and Skills Enhancement (EASE) Program: A Clinical Trial[NCT03432832] | 113 participants (Actual) | Interventional | 2018-01-30 | Completed | |||
| Placebo-Controlled Study of Risperidone for the Treatment of Children and Adolescents With Autism and Negative Behavioral Symptoms[NCT00005014] | Phase 3 | 101 participants (Actual) | Interventional | 1997-10-31 | Completed | ||
| Effect of PLAY Project Intervention Program on Children With Autism Spectrum Disorder: A Multi-center, Randomized Control Study in China[NCT05531669] | 200 participants (Anticipated) | Interventional | 2022-08-01 | Recruiting | |||
| Risperidone and Behavioral Therapy in Treatment of Children and Adolescents With Autistic Disorder[NCT00080145] | 124 participants (Actual) | Interventional | 2004-02-29 | Completed | |||
| Characterization of Endogenous Melatonin Profiles in Children With Autism Spectrum Disorder.[NCT00691080] | 58 participants (Actual) | Observational | 2007-09-30 | Completed | |||
| Pharmacological Treatment of Rett Syndrome by Stimulation of Synaptic Maturation With Recombinant Human IGF-1(Mecasermin [rDNA] Injection)[NCT01777542] | Phase 2 | 30 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Severe Aberrant Behavior Among Persons With Mental Retardation. Project III: Behavioral Selectivity of Atypical Neuroleptic Drugs: Effects on Cognitive and Social Behaviors[NCT00065273] | Phase 3 | 50 participants | Interventional | 1998-07-31 | Completed | ||
| Assessing the Feasibility, Acceptability, and Preliminary Efficacy of an Adaptive Intervention Approach for Children With Autism and Disruptive Behavior: A Pilot Study[NCT04204226] | 42 participants (Actual) | Interventional | 2019-12-17 | Completed | |||
| Efficacy And Safety Of Risperidone In The Treatment Of Children With Autistic Disorder And Other Pervasive Developmental Disorders: A Canadian, Multicenter, Double-Blind, Placebo-Controlled Study[NCT00261508] | Phase 3 | 80 participants (Actual) | Interventional | 1999-08-31 | Completed | ||
| Methylphenidate for Hyperactivity and Impulsiveness in Children and Adolescents With Pervasive Developmental Disorders[NCT00025779] | 60 participants | Interventional | 2001-10-31 | Completed | |||
| Neural Mechanisms of CBT for Anxiety in Children With Autism: Randomized Controlled Trial[NCT02725619] | 70 participants (Actual) | Interventional | 2016-04-30 | Completed | |||
| Neural Mechanisms of Cognitive-Behavioral Therapy for Anxiety in Children With Autism Spectrum Disorder: A Pilot Study[NCT02225808] | 10 participants (Actual) | Interventional | 2014-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measure of irritability symptoms of autism. Score range 0 to 45 (lower score = lesser severity). (NCT00576732)
Timeframe: Baseline and 6 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -3.5 |
| Risperidone Low Dose | -7.4 |
| Risperidone High Dose | -12.4 |
"Investigator evaluation of severity of illness and functional impairment on a 7-point scale (1=not ill, 2=very mild, 3=mild, 4=moderate, 5=marked, 6=severe, 7=extremely severe)." (NCT00576732)
Timeframe: Baseline and 6 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -0.3 |
| Risperidone Low Dose | -0.4 |
| Risperidone High Dose | -1.0 |
(NCT00576732)
Timeframe: Baseline and 6 months
| Intervention | mg/dL (Mean) |
|---|---|
| Placebo/RIS | 4.0 |
| Ris Low Dose/RIS | 3.5 |
| Ris High Dose/RIS | 2.3 |
(NCT00576732)
Timeframe: Baseline and 6 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| Placebo | -0.4 |
| Risperidone Low Dose | -0.1 |
| Risperidone High Dose | -0.3 |
Insulin resistance calculated using the homeostatic model assessment 1 (HOMA1) formula: fasting glucose (mmol/L) times fasting insulin (uU/L) divided by 22.5. HOMA-IR is a widely used clinical tool for estimating insulin resistance based upon the balance between glucose output and insulin secretion. Normal values should be close to 1, while an increase indicates a decrease in insulin sensitivity (or increase in insulin resistance), a potential predictor for the development of Type 2 Diabetes Mellitus. (NCT00576732)
Timeframe: Baseline and 6 months
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo/RIS | 0.09 |
| Ris Low Dose/RIS | 0.36 |
| Ris High Dose/RIS | 0.75 |
Insulin resistance calculated using the homeostatic model assessment 1 (HOMA1)formula: fasting glucose (mmol/L) times fasting insulin (uU/L) divided by 22.5. HOMA-IR is a widely used clinical tool for estimating insulin resistance based upon the balance between glucose output and insulin secretion. Normal values should be close to 1, while an increase indicates a decrease in insulin sensitivity (or increase in insulin resistance), a potential predictor for the development of Type 2 Diabetes Mellitus. (NCT00576732)
Timeframe: Baseline and 6 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 0.36 |
| Risperidone Low Dose | -0.10 |
| Risperidone High Dose | 0.45 |
ABC-I is a measure of irritability symptoms of autism with score range 0 to 45 (lower score = lesser severity). (NCT00576732)
Timeframe: 6 weeks
| Intervention | participants (Number) |
|---|---|
| Placebo | 14 |
| Risperidone Low Dose | 15 |
| Risperidone High Dose | 24 |
"Investigator impression of change over time from double-blind baseline on a 7-point scale (1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse)." (NCT00576732)
Timeframe: 6 weeks
| Intervention | participants (Number) |
|---|---|
| Placebo | 5 |
| Risperidone Low Dose | 5 |
| Risperidone High Dose | 19 |
Change in % of correct phonemes in each attempted stimulus (NCT04764539)
Timeframe: Seven weeks--each subject participated in the study twice a week over a 7-week period for a total of 14 sessions. The first and last sessions (session #1 and session #14) were reserved for pre-test and post-test language sample collection and assessment.
| Intervention | percentage of correct phonemes (Mean) |
|---|---|
| Stimuli Administered Via 2D Format on an iPad Pro | 19.75 |
| Stimuli Administered in 3D Format Via VR Goggles and Bone Conduction Headphones | 16.24 |
"Participants (aged 4 to 8 years) were given a pre- and post-test 15-minute language sample. MLU was calculated for tests and gain from pre-test to post-test was compared.~NOTE: This measure is calculated based on a change in the number of morphemes per utterance during pre-test and post-test language samples. During a five-minute period, two licensed speech-language pathologists (SLP) observed a parent interacting and talking with their child. Parents Both SLPs transcribed the subjects' speech and calculated a mean length of utterance (MLU) for each subject. MLU was calculated by determining how many bound and free morphemes were included within every spoken utterance produced by a subject. The total number of morphemes produced within the 5-minute period were then divided by total number of utterances, which then produced the MLU for each subject. This procedure was use for determining MLU in both the pre- and post-testing procedures." (NCT04764539)
Timeframe: Seven weeks--each subject participated in the study twice a week over a 7-week period for a total of 14 sessions. The first and last sessions (session #1 and session #14) were reserved for pre-test and post-test language sample collection and assessment.
| Intervention | Morphemes per utterance (Mean) |
|---|---|
| Stimuli Administered Via 2D Format on an iPad Pro | 0.5387 |
| Stimuli Administered in 3D Format Via VR Goggles and Bone Conduction Headphones | 0.2987 |
"15-minute pre- and post-testing was performed using speech recognition software and transcribed by a licensed speech pathologist. Differences pre and post intervention were compared across group and within groups.~NOTE: During our assessment, we used Google's native closed captioning function (a tool which uses machine learning to recognize and transcribe speech) and a third party app, Tactiq Pins, which allows users to keep a transcript of all speaker utterances during a call. We compared our video to the Tactiq Pin transcripts in order to measure any change in the amount of accurately transcribed spoken words between pre-test and post-test language samples. Specific transcription results for each group can be found in the data tables provided." (NCT04764539)
Timeframe: Seven weeks--each subject participated in the study twice a week over a 7-week period for a total of 14 sessions. The first and last sessions (session #1 and session #14) were reserved for pre-test and post-test language sample collection and assessment.
| Intervention | % of correctly transcribed words (Mean) |
|---|---|
| Stimuli Administered Via 2D Format on an iPad Pro | 1.388 |
| Stimuli Administered in 3D Format Via VR Goggles and Bone Conduction Headphones | 0 |
A type-token ratio measures the total number of unique words in a given segment of language. (NCT04764539)
Timeframe: Seven weeks--each subject participated in the study twice a week over a 7-week period for a total of 14 sessions. The first and last sessions (session #1 and session #14) were reserved for pre-test and post-test language sample collection and assessment.
| Intervention | number of unique words in a segment (Mean) |
|---|---|
| Stimuli Administered Via 2D Format on an iPad Pro | 30.158 |
| Stimuli Administered in 3D Format Via VR Goggles and Bone Conduction Headphones | 22.26 |
The change in response rate measures any significant differences in how often children responded to pre- and post-testing stimuli after having received treatment between the iPad Pro and VR goggles groups. A response is considered a verbal or non-verbal reaction (e.g., eye contact, gestures, vocalizations) to the stimuli presented during the therapy sessions. Higher response rates indicate better engagement and responsiveness to the treatment. The change in response rate is calculated as the value at the post-test time point minus the value at the pre-test time point, with positive numbers representing increases and negative numbers representing decreases in response rate. (NCT04764539)
Timeframe: Seven weeks--each subject participated in the study twice a week over a 7-week period for a total of 14 sessions. The first and last sessions (session #1 and session #14) were reserved for pre-test and post-test language sample collection and assessment.
| Intervention | Number of responses (Mean) |
|---|---|
| Stimuli Administered Via 2D Format on an iPad Pro | 5.67 |
| Stimuli Administered in 3D Format Via VR Goggles and Bone Conduction Headphones | 3.33 |
"Parent observations -- perceptions of changes in their children's motor-speech, behavioral, and social communication skills after having participated in the study~Scale title: Net Positive Changes Score Maximum possible value: 18 Minimum possible value: -2 Higher score is better." (NCT04764539)
Timeframe: Seven weeks--each subject participated in the study twice a week over a 7-week period for a total of 14 sessions. The first and last sessions (session #1 and session #14) were reserved for pre-test and post-test language sample collection and assessment.
| Intervention | Score on a scale (Mean) |
|---|---|
| Parents of Participants, Who Received VAST Stimuli Via a 2D Format on an iPad Pro | 11 |
| Parents of Participants, Who Received VAST Stimuli Through VR Goggles and Bone Conduction Headphones | 9.67 |
"The ABC-C is a global behavior checklist implemented for the measurement of drug and other treatment effects in populations with intellectual disability. Behavior based on 58 items that describe various behavioral problems.~Each item is rated on the parents perceived severity of the behavior. The answer options for each item are:~0 = Not a problem~= Problem but slight in degree~= Moderately serious problem~= Severe in degree~The measure is broken down into the following subscales with individual ranges as follows:~Subscale I (Irritability): 15 items, score range = 0-45 Subscale II (Lethargy): 16 items, score range = 0-48 Subscale III (Stereotypy): 7 items, score range = 0-21 Subscale IV (Hyperactivity): 16 items, score range = 0-48 Subscale V (Inappropriate Speech) was not included in the breakdown because it was not applicable (no participants in the study had verbal language)." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Subscale I | Visit 3 - First Intervention: Subscale I | Visit 5 - First Intervention: Subscale I | Visit 6 - Second Intervention: Subscale I | Visit 8 - Second Intervention: Subscale I | Visit 10 - Second Intervention: Subscale I | Follow-up: Subscale I (Irritability) | Visit 1 - First Intervention: Subscale II | Visit 3 - First Intervention: Subscale II | Visit 5 - First Intervention: Subscale II | Visit 6 - Second Intervention: Subscale II | Visit 8 - Second Intervention: Subscale II | Visit 10 - Second Intervention: Subscale II | Follow-up: Subscale II (Lethargy) | Visit 1 - First Intervention: Subscale III | Visit 3 - First Intervention: Subscale III | Visit 5 - First Intervention: Subscale III | Visit 6 - Second Intervention: Subscale III | Visit 8 - Second Intervention: Subscale III | Visit 10 - Second Intervention: Subscale III | Follow-up: Subscale III (Stereotypy) | Visit 1 - First Intervention: Subscale IV | Visit 3 - First Intervention: Subscale IV | Visit 5 - First Intervention: Subscale IV | Visit 6 - Second Intervention: Subscale IV | Visit 8 - Second Intervention: Subscale IV | Visit 10 - Second Intervention: Subscale IV | Follow-up: Subscale IV (Hyperactivity) | |
| Placebo First, Then rhIGF-1 | 9.00 | 9.00 | 7.00 | 7.00 | 4.00 | 5.00 | 3.00 | 13.00 | 11.00 | 9.00 | 11.00 | 8.00 | 6.00 | 6.00 | 13.00 | 10.00 | 11.00 | 11.00 | 10.00 | 8.00 | 8.00 | 13.00 | 12.00 | 11.00 | 11.00 | 7.00 | 10.00 | 9.00 |
| rhIGF-1 First, Then Placebo | 6.00 | 4.00 | 2.00 | 4.00 | 3.00 | 5.00 | 2.00 | 8.00 | 7.00 | 6.00 | 5.00 | 5.00 | 4.00 | 5.00 | 12.00 | 10.00 | 9.00 | 11.00 | 9.00 | 9.00 | 9.00 | 8.00 | 8.00 | 6.00 | 7.00 | 4.00 | 5.00 | 5.00 |
"Remaining subscales of the ADAMS that are not primary outcome measures include: Manic/hyperactive, Depressed mood, General anxiety, Obsessive/compulsive behavior.~The range for each subscale is as follows:~Manic/Hyperactive Behavior: 0-15 Depressed Mood: 0-21 General Anxiety: 0-21 Obsessive/Compulsive Behavior: 0-9~The higher the score for each subscale, the more problematic the behavior." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1- First Intervention: Manic/Hyperactive | Visit 2- First Intervention: Manic/Hyperactive | Visit 3- First Intervention: Manic/Hyperactive | Visit 4- First Intervention: Manic/Hyperactive | Visit 5- First Intervention: Manic/Hyperactive | Visit 6- Second Intervention: Manic/Hyperactive | Visit 7- Second Intervention: Manic/Hyperactive | Visit 8- Second Intervention: Manic/Hyperactive | Visit 9- Second Intervention: Manic/Hyperactive | Visit 10- First Intervention: Manic/Hyperactive | Follow-up: Manic/Hyperactive Subscale | Visit 1- First Intervention: Depressed Mood | Visit 2- First Intervention: Depressed Mood | Visit 3- First Intervention: Depressed Mood | Visit 4- First Intervention: Depressed Mood | Visit 5- First Intervention: Depressed Mood | Visit 6- Second Intervention: Depressed Mood | Visit 7- Second Intervention: Depressed Mood | Visit 8- Second Intervention: Depressed Mood | Visit 9- Second Intervention: Depressed Mood | Visit 10- Second Intervention: Depressed Mood | Follow-up: Depressed Mood Subscale | Visit 1- First Intervention: General Anxiety | Visit 2- First Intervention: General Anxiety | Visit 3- First Intervention: General Anxiety | Visit 4- First Intervention: General Anxiety | Visit 5- First Intervention: General Anxiety | Visit 6- Second Intervention: General Anxiety | Visit 7- Second Intervention: General Anxiety | Visit 8- Second Intervention: General Anxiety | Visit 9- Second Intervention: General Anxiety | Visit 10- Second Intervention: General Anxiety | Follow-up: General Anxiety Subscale | Visit 1- First Intervention: Obsessive Compulsive | Visit 2- First Intervention: Obsessive Compulsive | Visit 3- First Intervention: Obsessive Compulsive | Visit 4- First Intervention: Obsessive Compulsive | Visit 5- First Intervention: Obsessive Compulsive | Visit 6- Second Intervention: Obsessive Compulsive | Visit 7- Second Intervention: Obsessive Compulsive | Visit 8- Second Intervention: Obsessive Compulsive | Visit 9- Second Intervention: Obsessive Compulsive | Visit 10- First Intervention: Obsessive Compulsive | Follow-up: Obsessive Compulsive Behavior Subscale | |
| Placebo First, Then rhIGF-1 | 8.00 | 7.00 | 7.00 | 7.00 | 7.00 | 8.00 | 6.50 | 6.00 | 6.00 | 5.00 | 5.00 | 2.00 | 4.00 | 3.00 | 2.00 | 2.00 | 2.00 | 3.00 | 2.00 | 3.00 | 2.00 | 2.00 | 8.00 | 6.00 | 6.00 | 5.00 | 5.00 | 6.00 | 6.00 | 6.00 | 4.00 | 4.00 | 5.50 | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 3.50 |
| rhIGF-1 First, Then Placebo | 7.00 | 7.00 | 6.00 | 5.00 | 4.00 | 6.00 | 5.00 | 5.00 | 4.00 | 4.50 | 5.00 | 4.00 | 5.00 | 3.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 2.00 | 3.00 | 3.50 | 6.00 | 7.00 | 6.00 | 5.00 | 5.00 | 7.00 | 5.00 | 4.00 | 3.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 2.50 | 3.00 |
"The ADAMS is completed by the parent/caregiver/LAR and consists of 29 items which are scored on a 4-point rating scale that combines frequency and severity ratings. The instructions ask the rater to describe the individual's behavior over the last six months on the following scale: 0 if the behavior has not occurred, 1 if the behavior occurs occasionally or is a mild problem, 2 if the behavior occurs quite often or is moderate problem, or 3 if the behavior occurs a lot or is a severe problem.~The Social Avoidance subscale of the ADAMS will be used as a primary outcome measure for this trial. The range for this subscale is 0-21. The higher the subscale score, the more problematic the behavior." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 6.00 | 5.00 | 5.00 | 6.00 | 5.00 | 4.00 | 4.00 | 4.00 | 3.00 | 3.50 | 4.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 5.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 4.00 | 3.00 | 3.50 | 3.00 |
"Each time the patient was seen after the study intervention was initiated, the clinician compared the patient's overall clinical condition to the CGI-S score obtained at the baseline (visit 1) visit. Based on information collected, the clinician determined if any improvement occurred on the following 7-point scale: 1=Very much improved since the initiation of treatment; 2=Much improved; 3=Minimally improved; 4=No change from baseline (the initiation of treatment); 5=Minimally worse; 6=Much worse; 7=Very much worse since the initiation of treatment.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods
| Intervention | units on a scale (Median) | ||||
|---|---|---|---|---|---|
| Visit 3 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 8 - Second Intervention | Visit 10 - Second Intervention | |
| Placebo First, Then rhIGF-1 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
"This scale is used to judge the severity of the subject's disease prior to entry into the study. The clinician will rate the severity of behavioral symptoms at baseline on a 7-point scale from not impaired to the most impaired.~The scores that correspond to each possible grouping are as follows: 1=Normal, not at all impaired; 2=Borderline impaired; 3=Mildly impaired; 4=Moderately impaired; 5=Markedly impaired; 6=Severely impaired; 7=The most impaired.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods
| Intervention | units on a scale (Median) | |||||
|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 3 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 8 - Second Intervention | Visit 10 - Second Intervention | |
| Placebo First, Then rhIGF-1 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.50 |
"The CSBS-DP was designed to measure early communication and symbolic skills in infants and young children (that is, functional communication skills of 6 month to 2 year olds). The CSBS-DP measures skills from three composites: (a) Social (emotion, eye gaze, and communication); (b) Speech (sounds and words); and (c) Symbolic (understanding and object use) and asks about developmental milestones. The data reported are the composite scores for these three categories.~The possible scores for the three composite categories are as follows:~Social Composite = 0-48; Speech Composite = 0-40; Symbolic Composite = 0-51.~A higher score indicates more advanced abilities in that area." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Social | Visit 2: Social Composite Score | Visit 3: Social Composite Score | Visit 4: Social Composite Score | Visit 5: Social Composite Score | Visit 6 - Second Intervention: Social | Visit 7 - Second Intervention: Social | Visit 8 - Second Intervention: Social | Visit 9 - Second Intervention: Social | Visit 10 - Second Intervention: Social | Follow-up: Social Composite Score | Visit 1 - First Intervention: Speech | Visit 2 - First Intervention: Speech | Visit 3 - First Intervention: Speech | Visit 4 - First Intervention: Speech | Visit 5 - First Intervention: Speech | Visit 6 - Second Intervention: Speech | Visit 7 - Second Intervention: Speech | Visit 8 - Second Intervention: Speech | Visit 9 - Second Intervention: Speech | Visit 10 - Second Intervention: Speech | Follow-up: Speech Composite Score | Visit 1 - First Intervention: Symbolic | Visit 2 - First Intervention: Symbolic | Visit 3 - First Intervention: Symbolic | Visit 4 - First Intervention: Symbolic | Visit 5 - First Intervention: Symbolic | Visit 6 - Second Intervention: Symbolic | Visit 7 - Second Intervention: Symbolic | Visit 8 - Second Intervention: Symbolic | Visit 9 - Second Intervention: Symbolic | Visit 10 - Second Intervention: Symbolic | Follow-up: Symbolic Composite Score | |
| Placebo First, Then rhIGF-1 | 19.00 | 20.00 | 18.00 | 18.00 | 20.00 | 18.00 | 20.00 | 21.00 | 21.00 | 22.50 | 22.50 | 4.00 | 3.00 | 5.00 | 5.50 | 6.50 | 4.00 | 4.00 | 5.00 | 5.00 | 5.00 | 6.00 | 9.50 | 10.50 | 10.50 | 12.00 | 11.50 | 13.00 | 10.25 | 11.50 | 11.50 | 13.75 | 14.25 |
| rhIGF-1 First, Then Placebo | 22.00 | 24.00 | 24.00 | 24.00 | 23.00 | 28.00 | 25.00 | 27.00 | 29.00 | 27.00 | 28.00 | 7.00 | 5.00 | 8.00 | 5.00 | 8.00 | 8.50 | 7.00 | 6.50 | 5.00 | 7.25 | 6.00 | 14.00 | 14.50 | 15.00 | 14.00 | 16.50 | 18.50 | 17.00 | 17.00 | 18.00 | 17.00 | 18.00 |
"The Kerr clinical severity scale (Kerr scale) is a quantitative measure of global disease severity. The Kerr scale is a summation of individual items related to Rett syndrome phenotypic characteristics. The items are based on the severity or degree of abnormality of each characteristic on a discrete scale (0, 1, 2) with the highest level corresponding to the most severe or most abnormal presentations.~The possible range of scores is 0-48. The higher the score, the more severe the symptoms." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period
| Intervention | units on a scale (Median) | |||
|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 10 - Second Intervention | |
| Placebo First, Then rhIGF-1 | 16.50 | 15.00 | 15.00 | 14.00 |
| rhIGF-1 First, Then Placebo | 18.00 | 18.00 | 19.00 | 20.00 |
"The MSEL is a standardized developmental test for children ages 3 to 68 months consisting of five subscales: gross motor, fine motor, visual reception, expressive language, and receptive language.~The raw score is reported for each subscale domain. The potential score ranges are as follows:~Visual Reception: 33 items, score range=0-50, Fine Motor: 30 items, score range= 0-49, Receptive Language: 33 items, score range= 0-48, Expressive Language: 28 items, score range= 0-50. The gross motor subscale was not included in this population.~A higher raw score indicates more advanced abilities in that section." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period
| Intervention | units on a scale (Median) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1- First Intervention: Visual Reception | Visit 5- First Intervention: Visual Reception | Visit 6- Second Intervention: Visual Reception | Visit 10: Visual Reception Raw Score | Visit 1- First Intervention: Fine Motor | Visit 5- First Intervention: Fine Motor | Visit 6- Second Intervention: Fine Motor | Visit 10- Second Intervention: Fine Motor | Visit 1- First Intervention: Receptive Language | Visit 5- First Intervention: Receptive Language | Visit 6- Second Intervention: Receptive Language | Visit 10- Second Intervention: Receptive Language | Visit 1- First Intervention: Expressive Language | Visit 5- First Intervention: Expressive Language | Visit 6- Second Intervention: Expressive Language | Visit 10- Second Intervention: Expressive Language | |
| Placebo First, Then rhIGF-1 | 17.00 | 26.00 | 23.00 | 28.00 | 10.00 | 9.00 | 11.00 | 9.00 | 20.00 | 30.00 | 31.00 | 31.00 | 8.00 | 9.00 | 6.00 | 8.00 |
| rhIGF-1 First, Then Placebo | 26.00 | 39.50 | 42.00 | 44.00 | 7.00 | 7.00 | 10.00 | 8.50 | 25.50 | 32.00 | 38.00 | 36.50 | 9.00 | 8.00 | 10.00 | 8.00 |
"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 6.50 | 4.70 | 5.65 | 5.05 | 4.80 | 4.95 | 4.55 | 5.65 | 4.15 | 4.80 | 5.60 |
| rhIGF-1 First, Then Placebo | 8.80 | 4.80 | 5.35 | 5.10 | 5.15 | 5.20 | 4.65 | 5.00 | 5.15 | 5.05 | 5.08 |
"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 7.75 | 4.50 | 5.85 | 5.00 | 5.00 | 5.35 | 5.50 | 5.15 | 3.80 | 4.90 | 5.15 |
| rhIGF-1 First, Then Placebo | 6.35 | 5.25 | 5.95 | 5.40 | 5.45 | 7.10 | 5.85 | 5.00 | 5.13 | 4.95 | 5.20 |
"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 7.85 | 4.70 | 5.65 | 4.15 | 5.00 | 6.20 | 4.80 | 4.85 | 4.60 | 4.13 | 4.55 |
| rhIGF-1 First, Then Placebo | 5.70 | 5.00 | 5.20 | 5.35 | 5.10 | 5.35 | 4.95 | 5.15 | 5.25 | 4.55 | 5.10 |
"As part of each visit after the study intervention was initiated, the parent/caregiver was asked to compare the patient's overall clinical condition to the score obtained at the baseline (visit 1) visit. Based on information collected, the clinician determined if any improvement occurred on the following 7-point scale: 1=Very much improved since the initiation of treatment; 2=Much improved; 3=Minimally improved; 4=No change from baseline (the initiation of treatment); 5=Minimally worse; 6=Much worse; 7=Very much worse since the initiation of treatment.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 4.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
"The PGI-S is the parent version of the CGI-S. Parents/caregivers/LAR are asked to rate the severity of their child's symptoms at baseline on a 7-point scale from not at all impaired to the most impaired. The parents/caregivers/LAR will complete the PGI-S at each study visit.~The scores that correspond to each possible grouping are as follows:~1=Normal, not at all impaired; 2=Borderline impaired; 3=Mildly impaired; 4=Moderately impaired; 5=Markedly impaired; 6=Severely impaired; 7=The most impaired.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| rhIGF-1 First, Then Placebo | 6.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 6.00 | 6.00 | 5.00 | 4.00 |
"Respiratory data was collected using non-invasive respiratory inductance plethysmography from a BioCapture® recording device. BioCapture® is a child-friendly measurement device that can record from 1 to 12 physiological signal transducers in a time-locked manner. It can be configured with the pediatric chest and abdominal plethysmography bands and the 3 lead ECG signals we plan to use for monitoring cardiac safety throughout the study. Each transducer is placed on the patient independently to provide a customized fit that yields the highest signal quality for each patient irrespective of body shape and proportion. The transducer signals captured by the BioCapture® are transmitted wirelessly to a laptop computer where all signals are displayed in real-time.~The apnea index is given as apneas/hour. Data on apneas greater than or equal to 10 seconds are displayed below. The higher the frequency of apnea, the more severe the breathing abnormality." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods
| Intervention | Apneas/Hour (Median) | |||||
|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Apnea Index | Visit 3 - First Intervention: Apnea Index | Visit 5 - First Intervention: Apnea Index | Visit 6 - Second Intervention: Apnea Index | Visit 8 - Second Intervention: Apnea Index | Visit 10 - Second Intervention: Apnea Index | |
| Placebo First, Then rhIGF-1 | 7.58 | 4.80 | 6.93 | 7.90 | 7.28 | 8.91 |
| rhIGF-1 First, Then Placebo | 4.05 | 3.48 | 3.07 | 3.62 | 5.55 | 5.56 |
"The RSBQ is a parent-completed measure of abnormal behaviors typically observed in individuals with RTT. Each item, grouped into eight subscales, is scored on a Likert scale of 0-2, according to how well the item describes the individual's behavior. A score of 0 indicates the described item is not true, a score of 1 indicates the described item is somewhat or sometimes true, and a score of 2 indicates the described item is very true or often true.~The total sum of each subscale is reported. The higher the score, the more severe the symptoms of that subscale in the participant.~The range for each subscale is as follows:~General Mood: 0-16 Body rocking and expressionless face: 0-14 Hand behaviors: 0-12 Breathing Problems: 0-10 Repetitive Face Movements: 0-8 Night-time behaviors: 0-6 Walking Standing: 0-4~The fear/anxiety subscale was used as a primary outcome measure in this study and results can be found in that section." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1- First Intervention: General Mood | Visit 2- First Intervention: General Mood | Visit 3- First Intervention: General Mood | Visit 4- First Intervention: General Mood | Visit 5- First Intervention: General Mood | Visit 6- Second Intervention: General Mood | Visit 7- Second Intervention: General Mood | Visit 8- Second Intervention: General Mood | Visit 9- Second Intervention: General Mood | Visit 10- Second Intervention: General Mood | Follow-up: General Mood | Visit 1- First Intervention: Body Rocking | Visit 2- First Intervention: Body Rocking | Visit 3- First Intervention: Body Rocking | Visit 4- First Intervention: Body Rocking | Visit 5- First Intervention: Body Rocking | Visit 6- Second Intervention: Body Rocking | Visit 7- Second Intervention: Body Rocking | Visit 8- Second Intervention: Body Rocking | Visit 9- Second Intervention: Body Rocking | Visit 10- Second Intervention: Body Rocking | Followup: Body Rocking | Visit 1- First Intervention: Hand Behaviors | Visit 2- First Intervention: Hand Behaviors | Visit 3- First Intervention: Hand Behaviors | Visit 4- First Intervention: Hand Behaviors | Visit 5- First Intervention: Hand Behaviors | Visit 6- Second Intervention: Hand Behaviors | Visit 7- Second Intervention: Hand Behaviors | Visit 8- Second Intervention: Hand Behaviors | Visit 9- Second Intervention: Hand Behaviors | Visit 10- Second Intervention: Hand Behaviors | Follow-up: Hand Behaviors | Visit 1- First Intervention: Breathing Problems | Visit 2- First Intervention: Breathing Problems | Visit 3- First Intervention: Breathing Problems | Visit 4- First Intervention: Breathing Problems | Visit 5- First Intervention: Breathing Problems | Visit 6- Second Intervention: Breathing Problems | Visit 7- Second Intervention: Breathing Problems | Visit 8- Second Intervention: Breathing Problems | Visit 9- Second Intervention: Breathing Problems | Visit 10- Second Intervention: Breathing Problems | Follow-up: Breathing Problems | Visit 1- First Intervention: Repetitive Face Movem | Visit 2- First Intervention: Repetitive Face Movem | Visit 3- First Intervention: Repetitive Face Movem | Visit 4- First Intervention: Repetitive Face Movem | Visit 5- First Intervention: Repetitive Face Movem | Visit 6- Second Intervention: Repetitive Face Mov | Visit 7- Second Intervention: Repetitive Face Mov | Visit 8- Second Intervention: Repetitive Face Mov | Visit 9- Second Intervention: Repetitive Face Mov | Visit 10- Second Intervention: Repetitive Face Mov | Follow-up: Repetitive Face Movements | Visit 1- First Intervention: Night time Behaviors | Visit 2- First Intervention: Night time Behaviors | Visit 3- First Intervention: Night time Behaviors | Visit 4- First Intervention: Night time Behaviors | Visit 5- First Intervention: Night time Behaviors | Visit 6- Second Intervention: Night time Behavior | Visit 7- Second Intervention: Night time Behavior | Visit 8- Second Intervention: Night time Behavior | Visit 9- Second Intervention: Night time Behavior | Visit 10- Second Intervention: Night time Behavior | Follow-up: Night time Behaviors | Visit 1- First Intervention: Walking/Standing | Visit 2- First Intervention: Walking/Standing | Visit 3- First Intervention: Walking/Standing | Visit 4- First Intervention: Walking/Standing | Visit 5- First Intervention: Walking/Standing | Visit 6- Second Intervention: Walking/Standing | Visit 7- Second Intervention: Walking/Standing | Visit 8- Second Intervention: Walking/Standing | Visit 9- Second Intervention: Walking/Standing | Visit 10- Second Intervention: Walking/Standing | Follow-up: Walking/Standing | |
| Placebo First, Then rhIGF-1 | 7.00 | 5.00 | 6.00 | 5.00 | 5.00 | 4.00 | 5.50 | 5.00 | 6.00 | 4.00 | 5.50 | 6.00 | 5.00 | 5.00 | 6.00 | 5.00 | 4.00 | 5.00 | 5.00 | 4.00 | 5.00 | 4.50 | 8.00 | 9.00 | 8.00 | 8.00 | 8.00 | 9.00 | 8.00 | 8.00 | 8.00 | 7.00 | 7.50 | 6.00 | 4.00 | 5.00 | 5.00 | 5.00 | 6.00 | 4.50 | 6.00 | 5.00 | 6.00 | 5.00 | 2.00 | 2.00 | 3.00 | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 1.50 | 2.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 3.00 | 2.00 | 2.00 | 3.00 | 4.00 | 2.00 | 2.00 | 1.00 | 2.50 | 2.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 4.00 | 3.00 | 4.00 | 3.00 | 4.00 | 4.00 | 8.00 | 8.00 | 8.00 | 9.00 | 9.00 | 8.00 | 9.00 | 9.00 | 7.00 | 9.00 | 8.50 | 4.00 | 4.00 | 4.00 | 5.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 2.00 | 2.00 | 3.00 | 2.00 | 2.00 | 3.00 | 2.00 | 2.00 | 2.00 | 1.50 | 2.00 | 1.00 | 1.00 | 0.00 | 0.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
"The RSBQ is an informant/parent-completed measure of abnormal behaviors typically observed in individuals with RTT, which is completed by a parent/caregiver/LAR. Each item, grouped into eight domains/factors: General mood, Breathing problems, Body rocking and expressionless face, Hand behaviors, Repetitive face movements, Night-time behaviors, Fear/anxiety and Walking/standing), is scored on a Likert scale of 0-2, according to how well the item describes the individual's behavior. A score of 0 indicates the described item is not true, a score of 1 indicates the described item is somewhat or sometimes true, and a score of 2 indicates the described item is very true or often true.~The total sum of items in each subscale is reported.~For the fear/anxiety subscale, the sum total could be between 0-8. The higher the sum total score, the greater the frequency of fear/anxiety behaviors." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 4.00 | 5.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 4.00 | 3.50 |
| rhIGF-1 First, Then Placebo | 5.00 | 3.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 4.00 | 3.00 | 3.00 | 3.50 |
"The VABS-II is a survey designed to assess personal and social functioning. Within each domain (Communication, Daily Living Skills, Socialization, and Motor Skills), items can given a score of 2 if the participant successfully performs the activity usually; a 1 if the participant successfully performs the activity sometimes, or needs reminders; a 0 if the participant never performs the activity, and a DK if the parent/caregiver is unsure of the participant's ability for an item.~The raw scores in each sub-domain are reported and the ranges for these are as follows: [Communication Domain], Receptive Language=0-40, Expressive Language=0-108, Written Language=0-50; [Daily Living Skills Domain], Personal=0-82, Domestic=0-48, Community=0-88; [Socialization Domain], Interpersonal Relationships=0-76, Play and Leisure Time=0-62, Coping Skills=0-60; [Motor Skills Domain]: Gross Motor Skills=0-80, Fine Motor Skills=0-72.~A higher score indicates more advanced abilities." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Receptive | Visit 5 - First Intervention: Receptive | Visit 6 - Second Intervention: Receptive Language | Visit 10 - Second Intervention: Receptive Language | Visit 1 - First Intervention: Expressive | Visit 5 - First Intervention: Expressive | Visit 6 - Second Intervention: Expressive Lang. | Visit 10 - Second Intervention: Expressive Lang. | Visit 1 - First Intervention: Written | Visit 5 - First Intervention: Written | Visit 6: - Second Intervention Written Language | Visit 10 - Second Intervention: Written Language | Visit 1 - First Intervention: Personal | Visit 5 - First Intervention: Personal | Visit 6 - Second Intervention: Personal | Visit 10 - Second Intervention: Personal | Visit 1 - First Intervention: Domestic | Visit 5 - First Intervention: Domestic | Visit 6 - Second Intervention: Domestic | Visit 10 - Second Intervention: Domestic | Visit 1 - First Intervention: Community | Visit 5 - First Intervention: Community | Visit 6 - Second Intervention: Community | Visit 10 - Second Intervention: Community | Visit 1 - First Intervention: Interpersonal Rel. | Visit 5 - First Intervention: Interpersonal Rel. | Visit 6 - Second Intervention: Interpersonal Rel. | Visit 10 - Second Intervention: Interpersonal Rel. | Visit 1 - First Intervention: Play and Leisure | Visit 5 - First Intervention: Play and Leisure | Visit 6 - Second Intervention: Play and Leisure | Visit 10 - Second Intervention: Play and Leisure | Visit 1 - First Intervention: Coping Skills | Visit 5 - First Intervention: Coping Skills | Visit 6 - Second Intervention: Coping Skills | Visit 10 - Second Intervention: Coping Skills | Visit 1 - First Intervention: Gross Motor | Visit 5 - First Intervention: Gross Motor | Visit 6 - Second Intervention: Gross Motor | Visit 10 - Second Intervention: Gross Motor | Visit 1 - First Intervention: Fine Motor | Visit 5 - First Intervention: Fine Motor | Visit 6 - Second Intervention: Fine Motor | Visit 10 - Second Intervention: Fine Motor | |
| Placebo First, Then rhIGF-1 | 13.00 | 15.00 | 18.00 | 20.00 | 16.00 | 17.00 | 18.00 | 20.00 | 0.00 | 0.00 | 4.00 | 6.00 | 9.00 | 10.00 | 9.00 | 10.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 2.00 | 18.00 | 18.00 | 19.00 | 20.00 | 8.00 | 11.00 | 12.00 | 11.00 | 3.00 | 2.00 | 3.00 | 4.00 | 31.00 | 34.00 | 27.00 | 27.00 | 6.00 | 6.00 | 7.00 | 5.00 |
| rhIGF-1 First, Then Placebo | 18.00 | 21.00 | 22.00 | 24.50 | 18.00 | 22.00 | 25.00 | 24.00 | 4.00 | 5.00 | 7.00 | 7.00 | 8.00 | 9.00 | 8.50 | 9.50 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 | 3.00 | 5.00 | 5.00 | 21.00 | 22.00 | 21.00 | 22.50 | 13.00 | 12.00 | 13.00 | 12.50 | 3.00 | 4.00 | 6.00 | 4.50 | 10.00 | 10.00 | 11.50 | 10.50 | 2.00 | 3.00 | 4.00 | 4.00 |
22 reviews available for risperidone and Autistic Disorder
| Article | Year |
|---|---|
Autism Spectrum Disorder and Complementary-Integrative Medicine.
Topics: Autism Spectrum Disorder; Autistic Disorder; Child; Humans; Integrative Medicine; Quality of Life; R | 2023 |
Effects of Risperidone in Autistic Children and Young Adults: A Systematic Review and Meta-Analysis.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Female; Humans; Male; Risperidone; Treat | 2021 |
An update on medication management of behavioral disorders in autism.
Topics: Adolescent; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Atomoxetine | 2014 |
Complementary and alternative treatments for autism part 1: evidence-supported treatments.
Topics: Acetylcysteine; Animals; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Complementary Therap | 2015 |
Autism Spectrum Disorder: Primary Care Principles.
Topics: Antipsychotic Agents; Aripiprazole; Asperger Syndrome; Autism Spectrum Disorder; Autistic Disorder; | 2016 |
Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders.
Topics: Adolescent; Aggression; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Benzodiazepines; Chil | 2008 |
Aripiprazole for the treatment of irritability associated with autism.
Topics: Antipsychotic Agents; Aripiprazole; Autistic Disorder; Humans; Irritable Mood; Piperazines; Quinolon | 2011 |
[Diversity of obsessive-compulsive disorder and pharmacotherapy associated with obsessive-compulsive spectrum disorders].
Topics: Antipsychotic Agents; Autistic Disorder; Body Dysmorphic Disorders; Clomipramine; Comorbidity; Disru | 2011 |
Risperidone: a potential treatment for autism.
Topics: Antipsychotic Agents; Autistic Disorder; Clinical Trials as Topic; Humans; Risperidone | 2002 |
Autism.
Topics: Autistic Disorder; Behavior Therapy; Caseins; Child; Child, Preschool; Glutens; Humans; Risperidone | 2005 |
Autistic spectrum disorders 2: diagnosis and management.
Topics: Antipsychotic Agents; Autistic Disorder; Behavior Therapy; Caseins; Causality; Child; Diagnosis, Dif | 2006 |
Role of risperidone in children with autism spectrum disorder.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; Double-Blind | 2006 |
[Autistic disorder: current psychopharmacological treatments and areas of interest for future developments].
Topics: Antidepressive Agents; Antipsychotic Agents; Autistic Disorder; Clinical Trials as Topic; Clozapine; | 2006 |
Risperidone for autism spectrum disorder.
Topics: Antipsychotic Agents; Autistic Disorder; Humans; Randomized Controlled Trials as Topic; Risperidone | 2007 |
Autism spectrum disorders in early childhood: an overview for practicing physicians.
Topics: Asperger Syndrome; Autistic Disorder; Behavior Therapy; Behavioral Medicine; Child; Child Developmen | 2007 |
Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents.
Topics: Adolescent; Autistic Disorder; Child; Humans; Irritable Mood; Risperidone; Treatment Outcome | 2007 |
Antipsychotic medications in children and adolescents.
Topics: Adolescent; Adult; Age Factors; Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Cl | 1996 |
Sudden infant death syndrome, child sexual abuse, and child development.
Topics: Autistic Disorder; Child; Child Abuse, Sexual; Child, Preschool; Condylomata Acuminata; Fluoxetine; | 1999 |
Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Autistic Disorder; Brain; Child; Clinical Trials as Topic; | 2000 |
Assessment in multisite randomized clinical trials of patients with autistic disorder: the Autism RUPP Network. Research Units on Pediatric Psychopharmacology.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Humans; Neuropsychological Tests; Reproducibility of | 2000 |
Is there a basis for novel pharmacotherapy of autism?
Topics: Amino Acid Sequence; Animals; Antipsychotic Agents; Autistic Disorder; Buspirone; Dietary Supplement | 2000 |
Autism spectrum disorders: update of evaluation and treatment.
Topics: Antipsychotic Agents; Autistic Disorder; Brain; Child; Humans; Magnetic Resonance Imaging; Risperido | 2001 |
62 trials available for risperidone and Autistic Disorder
| Article | Year |
|---|---|
Comparing the Effect of Risperidone, Virtual Reality and Risperidone on Social Skills, and Behavioral Problems in Children with Autism: A Follow-up Randomized Clinical Trial.
Topics: Autistic Disorder; Child; Follow-Up Studies; Humans; Problem Behavior; Risperidone; Social Skills; V | 2021 |
Intrathecal autologous bone marrow stem cell therapy in children with autism: A randomized controlled trial.
Topics: Autism Spectrum Disorder; Autistic Disorder; Bone Marrow; Cell- and Tissue-Based Therapy; Child; Hum | 2021 |
Simvastatin as an Adjunctive Therapy to Risperidone in Treatment of Autism: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Dose-Response Relationship, Drug; | 2018 |
l-Carnosine As an Adjunctive Therapy to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Antipsychotic Agents; Autism Spectrum Disorder; Autistic Disorder; Carnosine; Child; Child, Preschoo | 2018 |
Palmitoylethanolamide as adjunctive therapy for autism: Efficacy and safety results from a randomized controlled trial.
Topics: Amides; Anti-Inflammatory Agents, Non-Steroidal; Autistic Disorder; Child; Child, Preschool; Double- | 2018 |
A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Body Weight; Child; Child, Presch | 2014 |
Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial.
Topics: Antipsychotic Agents; Appetite; Autistic Disorder; Child; Child, Preschool; Double-Blind Method; Dru | 2013 |
A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Cystine; Double-Blind | 2013 |
Galantamine efficacy and tolerability as an augmentative therapy in autistic children: A randomized, double-blind, placebo-controlled trial.
Topics: Antipsychotic Agents; Autistic Disorder; Checklist; Child; Child Behavior; Child, Preschool; Choline | 2014 |
An open-label extension study of the safety and efficacy of risperidone in children and adolescents with autistic disorder.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Body Mass Index; Child; Child, Preschool; Doubl | 2013 |
Change in plasma cytokine levels during risperidone treatment in children with autism.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Cytokines; Female; Hum | 2014 |
A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism.
Topics: Ambulatory Care; Autistic Disorder; Buspirone; Child; Double-Blind Method; Drug Therapy, Combination | 2015 |
A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: Effects on aberrant behavior in children with autism.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child Behavior Disorders; Child, Preschool; Double-B | 2015 |
Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial.
Topics: Adolescent; Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Double-Bli | 2015 |
Initial severity and efficacy of risperidone in autism: Results from the RUPP trial.
Topics: Adolescent; Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Double-Bli | 2016 |
Minocycline as Adjunctive Treatment to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind Placebo-Controlled Trial.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Double-Blind Method; Drug Therapy, | 2016 |
Cognitive effects of risperidone in children with autism and irritable behavior.
Topics: Adolescent; Autistic Disorder; Child; Child Behavior Disorders; Child, Preschool; Cognition; Cogniti | 2008 |
Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism.
Topics: Antipsychotic Agents; Autistic Disorder; Behavioral Symptoms; Child; Child, Preschool; Developmental | 2010 |
Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Dose-Response Relation | 2010 |
Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Dose-Response Relationship, Drug; | 2010 |
Risperidone-related improvement of irritability in children with autism is not associated with changes in serum of epidermal growth factor and interleukin-13.
Topics: Adolescent; Anti-Inflammatory Agents; Antipsychotic Agents; Autistic Disorder; Biomarkers; Child; Ch | 2011 |
Effects of risperidone and parent training on adaptive functioning in children with pervasive developmental disorders and serious behavioral problems.
Topics: Adaptation, Psychological; Adolescent; Antipsychotic Agents; Asperger Syndrome; Autistic Disorder; C | 2012 |
Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial.
Topics: Antipsychotic Agents; Autistic Disorder; Celecoxib; Child; Child, Preschool; Cyclooxygenase 2 Inhibi | 2013 |
Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial.
Topics: Autistic Disorder; Child; Child, Preschool; Double-Blind Method; Drug Therapy, Combination; Female; | 2013 |
Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study.
Topics: Adolescent; Autistic Disorder; Child; Child, Preschool; Double-Blind Method; Female; Humans; Male; P | 2013 |
Risperidone in children with autism and serious behavioral problems.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior; Child, Preschool; Double | 2002 |
Risperidone in children with autism and serious behavioral problems.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior; Child, Preschool; Double | 2002 |
Risperidone in children with autism and serious behavioral problems.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior; Child, Preschool; Double | 2002 |
Risperidone in children with autism and serious behavioral problems.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior; Child, Preschool; Double | 2002 |
Risperidone in children with autism and serious behavioral problems.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior; Child, Preschool; Double | 2002 |
Risperidone in children with autism and serious behavioral problems.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior; Child, Preschool; Double | 2002 |
Risperidone in children with autism and serious behavioral problems.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior; Child, Preschool; Double | 2002 |
Risperidone in children with autism and serious behavioral problems.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior; Child, Preschool; Double | 2002 |
Risperidone in children with autism and serious behavioral problems.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior; Child, Preschool; Double | 2002 |
Risperidone in children with autism and serious behavioral problems.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior; Child, Preschool; Double | 2002 |
Risperidone in children with autism and serious behavioral problems.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior; Child, Preschool; Double | 2002 |
Risperidone in children with autism and serious behavioral problems.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior; Child, Preschool; Double | 2002 |
Risperidone in children with autism and serious behavioral problems.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior; Child, Preschool; Double | 2002 |
Risperidone in children with autism and serious behavioral problems.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior; Child, Preschool; Double | 2002 |
Risperidone in children with autism and serious behavioral problems.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior; Child, Preschool; Double | 2002 |
Risperidone in children with autism and serious behavioral problems.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior; Child, Preschool; Double | 2002 |
Risperidone in children with autism and serious behavioral problems.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior; Child, Preschool; Double | 2002 |
Risperidone in children with autism and serious behavioral problems.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior; Child, Preschool; Double | 2002 |
Risperidone in children with autism and serious behavioral problems.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior; Child, Preschool; Double | 2002 |
Risperidone in children with autism and serious behavioral problems.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior; Child, Preschool; Double | 2002 |
Risperidone in children with autism and serious behavioral problems.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior; Child, Preschool; Double | 2002 |
Risperidone in children with autism and serious behavioral problems.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior; Child, Preschool; Double | 2002 |
Risperidone in children with autism and serious behavioral problems.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior; Child, Preschool; Double | 2002 |
Risperidone in children with autism and serious behavioral problems.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior; Child, Preschool; Double | 2002 |
Risperidone in children with autism and serious behavioral problems.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior; Child, Preschool; Double | 2002 |
Multimodal evaluation of risperidone for destructive behavior: functional analysis, direct observations, rating scales, and psychiatric impressions.
Topics: Adult; Aggression; Antipsychotic Agents; Autistic Disorder; Coffin-Lowry Syndrome; Cross-Over Studie | 2002 |
Risperidone improves behavior in children with autism.
Topics: Adolescent; Autistic Disorder; Child; Child Behavior Disorders; Child, Preschool; Dose-Response Rela | 2002 |
Rate-decreasing effects of the atypical neuroleptic risperidone attenuated by conditions of reinforcement in a woman with mental retardation.
Topics: Adult; Antipsychotic Agents; Attention; Autistic Disorder; Behavior Therapy; Bipolar Disorder; Discr | 2003 |
Use of functional analysis methodology in the evaluation of medication effects.
Topics: Adult; Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Autist | 2003 |
Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials.
Topics: Adolescent; Adult; Affect; Aggression; Autistic Disorder; Child; Clinical Trials as Topic; Dopamine | 2003 |
[An open trial of risperidone in autistic children].
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child Behavior; Child, Preschool; Dopamine Antagonis | 2003 |
Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications.
Topics: Autistic Disorder; Child; Child, Preschool; Drug Tolerance; Female; Humans; Isoxazoles; Male; Palipe | 2004 |
Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Autistic Disorder; Body Mass Index; Body Weight; Chil | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Communication Disorders; Conduct Disorde | 2005 |
Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months.
Topics: Adolescent; Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior Disorders; Ch | 2005 |
Self injurious behavior in autism: clinical aspects and treatment with risperidone.
Topics: Antipsychotic Agents; Autistic Disorder; Brain; Brain Chemistry; Child; Dopamine; Dose-Response Rela | 2006 |
Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior Disorders; Child, Prescho | 2005 |
Assessment of the integrity of study blindness in a pediatric clinical trial of risperidone.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Double-Blind Method; H | 2005 |
Acute and long-term safety and tolerability of risperidone in children with autism.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Autistic Disorder; Body M | 2005 |
A crossover study of risperidone in children, adolescents and adults with mental retardation.
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Autistic Disorder; Child; Cross-Over Studies; D | 2006 |
Risperidone and adaptive behavior in children with autism.
Topics: Activities of Daily Living; Adaptation, Psychological; Adolescent; Antipsychotic Agents; Autistic Di | 2006 |
Effects of short- and long-term risperidone treatment on prolactin levels in children with autism.
Topics: Adolescent; Analysis of Variance; Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; | 2007 |
Risperidone in children with autism: randomized, placebo-controlled, double-blind study.
Topics: Autistic Disorder; Child; Child, Preschool; Communication; Dopamine Antagonists; Double-Blind Method | 2006 |
Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Double-Blind Method; Female; Human | 2007 |
Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy.
Topics: Antipsychotic Agents; Anxiety; Autistic Disorder; Behavior Therapy; Child Behavior Disorders; Child, | 2006 |
Parent satisfaction in a multi-site acute trial of risperidone in children with autism: a social validity study.
Topics: Adolescent; Adult; Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Consumer Behavi | 2007 |
Dietary status and impact of risperidone on nutritional balance in children with autism: a pilot study.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Body Weight; Child; Child Nutritional Physiolog | 2006 |
A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Diagnostic and Statistical Manual | 2008 |
Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. An open label maintenance study.
Topics: Adolescent; Adolescent Behavior; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior; Dos | 2008 |
Risperidone versus haloperidol in children and adolescents with AD : a randomized, controlled, double-blind trial.
Topics: Adolescent; Alanine Transaminase; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior Dis | 2008 |
Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: a naturalistic study.
Topics: Adolescent; Attention Deficit and Disruptive Behavior Disorders; Autistic Disorder; Central Nervous | 2008 |
An open clinical trial of risperidone monotherapy in young children with autistic disorder.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Humans; Pilot Projects; Psychiatri | 1997 |
An open trial of risperidone in young autistic children.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Humans; Male; Matched-Pair Analysi | 1998 |
A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders.
Topics: Adolescent; Adult; Age Factors; Aggression; Antipsychotic Agents; Autistic Disorder; Child Developme | 1998 |
Assessment in multisite randomized clinical trials of patients with autistic disorder: the Autism RUPP Network. Research Units on Pediatric Psychopharmacology.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Humans; Neuropsychological Tests; Reproducibility of | 2000 |
Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Female; Humans; Male; Psychiatric Status | 2000 |
Open trial of risperidone in 24 young children with pervasive developmental disorders.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; Child, Presc | 2001 |
Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism.
Topics: Adolescent; Adult; Aged; Aggression; Antipsychotic Agents; Autistic Disorder; Child; Cross-Over Stud | 2001 |
Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness.
Topics: Adolescent; Analysis of Variance; Antipsychotic Agents; Autistic Disorder; Child; Dyskinesia, Drug-I | 2002 |
Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Controlle | 2001 |
81 other studies available for risperidone and Autistic Disorder
| Article | Year |
|---|---|
Novel role of peroxisome proliferator activated receptor-α in valproic acid rat model of autism: Mechanistic study of risperidone and metformin monotherapy versus combination.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Fema | 2022 |
Low-Dose Risperidone for an Autistic Child with Comorbid ARFID and Misophonia.
Topics: Autism Spectrum Disorder; Autistic Disorder; Avoidant Restrictive Food Intake Disorder; Child; Feedi | 2022 |
Agomelatine Monotherapy for Autism-A Case Report.
Topics: Antipsychotic Agents; Aripiprazole; Autism Spectrum Disorder; Autistic Disorder; Humans; Risperidone | 2022 |
The comparative effectiveness of metformin and risperidone in a rat model of valproic acid-induced autism, Potential role for enhanced autophagy.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Autophagy; Disease Models, Animal; Female; Hum | 2023 |
Risperidone impedes glutamate excitotoxicity in a valproic acid rat model of autism: Role of ADAR2 in AMPA GluA2 RNA editing.
Topics: Adenosine Deaminase; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Autism Spect | 2023 |
Risperidone accelerates bone loss in rats with autistic-like deficits induced by maternal lipopolysaccharides exposure.
Topics: Animals; Animals, Newborn; Autistic Disorder; Behavior, Animal; Biomechanical Phenomena; Bone Resorp | 2020 |
Leukemia-like megaloblastic anemia in an autistic child receiving risperidone and valproic acid.
Topics: Anemia, Megaloblastic; Autistic Disorder; Child; Humans; Leukemia; Risperidone; Valproic Acid; Vitam | 2020 |
N-acetylcysteine is effective as add-on therapy to risperidone-based combination for children with autistic disorders.
Topics: Acetylcysteine; Antipsychotic Agents; Autistic Disorder; Child; Humans; Irritable Mood; Risperidone | 2022 |
Pharmacogenomics and Efficacy of Risperidone Long-Term Treatment in Thai Autistic Children and Adolescents.
Topics: Adolescent; Adolescent Behavior; Age Factors; Aggression; Autistic Disorder; Chi-Square Distribution | 2017 |
DRD3 Ser9Gly Polymorphism and Its Influence on Risperidone Response in Autistic Children.
Topics: Adolescent; Alleles; Autistic Disorder; Child; Child, Preschool; Female; Genotype; Glycine; Humans; | 2017 |
A patient with delusional infestation by proxy: Issues for vulnerable adults.
Topics: Adult Children; Antipsychotic Agents; Autistic Disorder; Delusional Parasitosis; Female; Humans; Mal | 2018 |
Risperidone-Induced Tardive Dyskinesia in an Autistic Child.
Topics: Adolescent; Autistic Disorder; Dopamine Antagonists; Humans; Male; Risperidone; Tardive Dyskinesia | 2018 |
Priapism associated with risperidone in a 21-year-old male with autism.
Topics: Antipsychotic Agents; Autistic Disorder; Humans; Male; Priapism; Recurrence; Risperidone; Young Adul | 2013 |
Psychopharmacological treatment in children and adolescents with autism spectrum disorders in Germany.
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Autistic Disorder; Central Nervous System Stimula | 2013 |
Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: a chart review study.
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Child; Child D | 2015 |
Risperidone and the 5-HT2A receptor antagonist M100907 improve probabilistic reversal learning in BTBR T + tf/J mice.
Topics: Animals; Antipsychotic Agents; Autistic Disorder; Disease Models, Animal; Fluorobenzenes; Male; Mice | 2014 |
Risperidone-associated urinary incontinence in patients with autistic disorder with mental retardation.
Topics: Adult; Aged; Antipsychotic Agents; Autistic Disorder; Fecal Incontinence; Female; Humans; Intellectu | 2014 |
Lack of effect of risperidone on core autistic symptoms: data from a longitudinal study.
Topics: Aggression; Autistic Disorder; Child; Child, Preschool; Female; Humans; Longitudinal Studies; Male; | 2014 |
Conflicts in family-centered pediatric care for patients with autism.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Antidepressive Agents; Antipsychotic Agents; Autistic D | 2015 |
From the Editor-in-Chief's Desk.
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Central Nerv | 2015 |
Multifocal atrial tachycardia caused by risperidone.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Electrocardiography; Humans; Male; Risperidone; | 2016 |
Effectiveness of switching from oral ziprasidone to risperidone in a patient with comorbid autistic disorder, profound intellectual disability, Gilbert syndrome, and exacerbation of psychosis.
Topics: Adult; Antipsychotic Agents; Autistic Disorder; Comorbidity; Gilbert Disease; Humans; Intellectual D | 2016 |
Risperidone-Induced Acute Respiratory Distress in an Adolescent with Autism.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Humans; Male; Respiratory Distress Syndrome; Ri | 2016 |
Comparing Efficacy and Side Effects of Memantine vs. Risperidone in the Treatment of Autistic Disorder.
Topics: Autistic Disorder; Child; Child, Preschool; Dopamine Agents; Dose-Response Relationship, Drug; Drug- | 2017 |
Treatment of Autism Spectrum Disorder in Children and Adolescents.
Topics: Adolescent; Aripiprazole; Autism Spectrum Disorder; Autistic Disorder; Child; Humans; Irritable Mood | 2016 |
Impact of risperidone on leptin and insulin in children and adolescents with autistic spectrum disorders.
Topics: Adiponectin; Adolescent; Antipsychotic Agents; Autistic Disorder; Blood Glucose; C-Reactive Protein; | 2017 |
Does risperidone improve hyperacusia in children with autism?
Topics: Antipsychotic Agents; Autistic Disorder; Child, Preschool; Female; Humans; Hyperacusis; Risperidone; | 2009 |
[Differences in cerebral blood flow following risperidone treatment in children with autistic disorder].
Topics: Antipsychotic Agents; Autistic Disorder; Cerebrovascular Circulation; Child; Corpus Callosum; Female | 2009 |
Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability.
Topics: Adolescent; Autistic Disorder; Biomarkers, Pharmacological; Child; Child, Preschool; Controlled Clin | 2010 |
Examining risperidone use in those diagnosed with autism 1 year after FDA approval.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Autistic Disorder; Child; Humans; Intellectua | 2010 |
Fluoxetine but not risperidone increases sociability in the BTBR mouse model of autism.
Topics: Animals; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Fluoxetine; Male; Mice; Risper | 2011 |
Risperidone: switching from brand name to generic.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Drugs, Generic; Female; Humans; Male; Ri | 2010 |
[Treatment of behavioral disorders by risperidone in children with autism].
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child Behavior Disorders; Child, Preschool; Female; | 2011 |
The treatment of autistic children with risperidone.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Humans; Male; Risperid | 2011 |
Risperidone rechallenge for marked liver function test abnormalities in an autistic child.
Topics: Antipsychotic Agents; Autistic Disorder; Chemical and Drug Induced Liver Injury; Child, Preschool; D | 2011 |
Risperidone and double incontinence in a child with autism.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Fecal Incontinence; Humans; Male; Risperidone; Urina | 2011 |
GABAB-mediated rescue of altered excitatory-inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction.
Topics: Animals; Autistic Disorder; Baclofen; Disease Models, Animal; Evoked Potentials, Auditory; Explorato | 2012 |
Treatments: In the waiting room.
Topics: Adolescent; Adult; Animals; Aripiprazole; Autistic Disorder; Brain; Child; Clinical Trials as Topic; | 2012 |
Risperidone-induced paroxysmal perceptual alteration in a child with autism.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Hallucinations; Humans; Male; Perceptual Disorders; | 2012 |
The autistic-spectrum disorders.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; Child, Presc | 2002 |
Risperidone in the treatment of autistic Thai children under 4 years of age.
Topics: Autistic Disorder; Child, Preschool; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Ad | 2002 |
Risperidone in children with autism and serious behavioral problems.
Topics: Antipsychotic Agents; Autistic Disorder; Behavior Therapy; Child; Humans; Risperidone | 2002 |
Risperidone in children with autism and serious behavioral problems.
Topics: Adolescent; Adult; Antipsychotic Agents; Autistic Disorder; Humans; Hyperprolactinemia; Hypogonadism | 2002 |
Risperidone in children with autism and serious behavioral problems.
Topics: Antipsychotic Agents; Autistic Disorder; Bipolar Disorder; Child; Humans; Male; Priapism; Psychotic | 2002 |
A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; Child, Presc | 2003 |
Tardive dyskinesia in an autistic patient treated with risperidone.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Dyskinesia, Drug-Induced; Humans; Male; Risperi | 2004 |
International adoption: a four-year-old child with unusual behaviors adopted at six months of age.
Topics: Adoption; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Child Behavior Disorders | 2004 |
Short-term efficacy and safety of risperidone in young children with autistic disorder (AD).
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Diagnostic and Statist | 2004 |
Methylphenidate an effective treatment for ADHD?
Topics: Adrenergic alpha-Agonists; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Auti | 2004 |
Occurrence of priapism with risperidone-paroxetine combination in an autistic child.
Topics: Adolescent; Autistic Disorder; Drug Therapy, Combination; Humans; Male; Paroxetine; Priapism; Risper | 2004 |
Research knowledge among parents of children participating in a randomized clinical trial.
Topics: Adolescent; Antipsychotic Agents; Attitude to Health; Autistic Disorder; Child; Child, Preschool; Co | 2005 |
Use of risperidone in developmentally disabled children.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; Diagnosis, D | 2005 |
Risperidone in a very young child with PDD.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; Child, Presc | 2005 |
Risperidone for the core symptom domains of autism.
Topics: Antipsychotic Agents; Autistic Disorder; Clinical Trials as Topic; Humans; Multicenter Studies as To | 2006 |
Risperidone: new indication. Behavioural disorders in children with autism or mental disabilities: no progress.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior Disorders; Child, Prescho | 2006 |
Risperidone and late onset tics.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Dyskinesia, Drug-Induced; Female; Follow | 2006 |
Risperidone induced oedema in a child with learning disability and autism.
Topics: Adolescent; Autistic Disorder; Dopamine Antagonists; Dose-Response Relationship, Drug; Edema; Epilep | 2006 |
The challenges of psychopharmacological management of children with severe developmental disabilities.
Topics: Anticonvulsants; Antipsychotic Agents; Autistic Disorder; Caregivers; Child; Developmental Disabilit | 2006 |
The practical search.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior Disorders; Evidence-Based | 2007 |
Antipsychotic drugs in children with autism.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior Disorders; Humans; Risper | 2007 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Risperidone approved for the treatment of serious behavioral problems in children with autism.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child Behavior Disorders; Child Psychiatry; Humans; | 2007 |
Risperidone-induced enuresis in two children with autistic disorder.
Topics: Antipsychotic Agents; Autistic Disorder; Benzodiazepines; Child; Diurnal Enuresis; Humans; Intellect | 2007 |
Use of medication for the management of behavior problems among adults with intellectual disabilities: a clinicians' consensus survey.
Topics: Adult; Aggression; Antipsychotic Agents; Attitude of Health Personnel; Autistic Disorder; Carbamazep | 2008 |
Risperidone-induced double incontinence.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Fecal Incontinence; Female; Humans; Inte | 2008 |
Abnormal movements with the addition of clindamycin to risperidone in a girl with autism.
Topics: Adolescent; Anti-Bacterial Agents; Antipsychotic Agents; Autistic Disorder; Clindamycin; Drug Therap | 2008 |
How do I decide whether or not to use medication for my child with autism? Should I try behavior therapy first?
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Behavior Therapy; Child; Clinical Trials as Top | 2008 |
Risperidone in the treatment of pervasive developmental disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Perv | 1994 |
Enuresis with combined risperidone and SSRI use.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; | 1996 |
Case study: anorexia nervosa and autistic disorder in an adolescent girl.
Topics: Adolescent; Anorexia Nervosa; Antipsychotic Agents; Autistic Disorder; Behavior Therapy; Combined Mo | 1996 |
Drug therapy in autism.
Topics: Anti-Anxiety Agents; Antipsychotic Agents; Autistic Disorder; Buspirone; Child; Depression; Drug The | 1997 |
Risperidone and explosive aggressive autism.
Topics: Activities of Daily Living; Adolescent; Adult; Aggression; Antipsychotic Agents; Autistic Disorder; | 1997 |
Risperidone in young children with pervasive developmental disorders and other developmental disabilities.
Topics: Aggression; Autistic Disorder; Child; Child Development Disorders, Pervasive; Child, Preschool; Huma | 1996 |
Risperidone and refusal to eat.
Topics: Antipsychotic Agents; Autistic Disorder; Child, Preschool; Feeding and Eating Disorders; Humans; Mal | 1998 |
The irony of autism.
Topics: Adult; Age Factors; Antipsychotic Agents; Autistic Disorder; Humans; Personality Inventory; Psychiat | 1998 |
Risperidone for insomnia in PDDs.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Dose-Response Relationship, Drug; | 1998 |
Brief report: two-year control of behavioral symptoms with risperidone in two profoundly retarded adults with autism.
Topics: Adult; Autistic Disorder; Compulsive Behavior; Dopamine Antagonists; Female; Gynecomastia; Humans; I | 1999 |
Risperidone in the treatment of two very young children with autism.
Topics: Antipsychotic Agents; Autistic Disorder; Child, Preschool; Humans; Infant; Male; Risperidone | 1999 |
Risperidone monotherapy in preschool children with pervasive developmental disorders.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child Behavior Disorders; Child Development Disorder | 2001 |
Open-label risperidone treatment of 6 children and adolescents with autism.
Topics: Adolescent; Autistic Disorder; Child; Child, Preschool; Female; Humans; Male; Risperidone; Treatment | 2001 |
Side-effects of risperidone therapy mimicking cerebrospinal fluid shunt malfunction: implications for clinical monitoring and management.
Topics: Adult; Antipsychotic Agents; Autistic Disorder; Cerebrospinal Fluid Shunts; Female; Humans; Hydrocep | 2002 |